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Highlights: 
 The application of low intensity TES in humans appears to be safe; 
 The profile of AEs in terms of frequency, magnitude and type is comparable in 
different populations; 
 Structured checklists and interviews as recommended procedures are provided 
in this paper; 
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Abstract 
Low intensity transcranial electrical stimulation (TES) in humans, encompassing 
transcranial direct current (tDCS), transcutaneous spinal Direct Current Stimulation 
(tsDCS), transcranial alternating current (tACS), and transcranial random noise (tRNS) 
stimulation or their combinations, appears to be safe. No serious adverse events (SAEs) 
have been reported so far in over 18,000 sessions administered to healthy subjects, 
neurological and psychiatric patients, as summarized here. Moderate adverse events 
(AEs), as defined by the necessity to intervene, are rare, and include skin burns with 
tDCS due to suboptimal electrode-skin contact. Very rarely mania or hypomania was 
induced in patients with depression (11 documented cases), yet a causal relationship is 
difficult to prove because of the low incidence rate and limited numbers of subjects in 
controlled trials. Mild AEs (MAEs) include headache and fatigue following stimulation as 
well as prickling and burning sensations occurring during tDCS at peak-to-baseline 
intensities of 1-2 mA and during tACS at higher peak-to-peak intensities above 2 mA.  
The prevalence of published AEs is different in studies specifically assessing AEs 
vs. those not assessing them, being higher in the former. AEs are frequently reported by 
individuals receiving placebo stimulation. The profile of AEs in terms of frequency, 
magnitude and type is comparable in healthy and clinical populations, and this is also 
the case for more vulnerable populations, such as children, elderly persons, or pregnant 
women. Combined interventions (e.g., co-application of drugs, electrophysiological 
measurements, neuroimaging) were not associated with further safety issues.  
Safety is established for low-intensity ‘conventional’ TES defined as <4 mA, up to 
60 min duration per day. Animal studies and modeling evidence indicate that brain 
injury could occur at predicted current densities in the brain of 6.3 to 13 A/m2 that are 
over an order of magnitude above those produced by tDCS in humans. Using AC 
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stimulation fewer AEs were reported compared to DC. In specific paradigms with 
amplitudes of up to 10 mA, frequencies in the kHz range appear to be safe. 
In this paper we provide structured interviews and recommend their use in 
future controlled studies, in particular when trying to extend the parameters applied. 
We also discuss recent regulatory issues, reporting practices and ethical issues. These 
recommendations achieved consensus in a meeting, which took place in Göttingen, 
Germany, on September 6-7, 2016 and were refined thereafter by email correspondence.  
 
Keywords: tDCS, tACS, TES, safety, adverse effects 
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1. Introduction 
The aim of this review is to update the safety of low-intensity electric stimulation 
based on available published research and clinical data in animal models and in human 
studies until the end of 2016. The essentials of the present manuscript were agreed 
upon at a two-day safety conference held in Göttingen, Germany on 6-7th September, 
2016. Participants included research and clinical experts from neurophysiology, 
neurology, cognitive neuroscience and psychiatry. Representatives of transcranial 
electrical stimulation (TES) equipment manufacturers contributed to regulatory issues. 
For the purposes of this review, data from published articles that encompassed more 
than 18,000 stimulation sessions in ~ 8,000 subjects, according to a recent review 
(Bikson et al. , 2016b), using low intensity stimulation (< 4 mA; see definitions below) 
up to 60 min duration/day were included. Literature searches investigated by experts 
on the related fields covered studies using transcranial direct current stimulation 
(tDCS), alternating current stimulation (tACS) and random noise stimulation (tRNS), 
with key words Adverse Events (AE) or Reactions (AR) and / or safety (see definitions 
below), in order to assess stimulation-related risks and to better understand of the risk-
benefit ratio of these procedures. We relied on summarizing and interpreting data on (1) 
available animal studies, (2) computational modeling and (3) testing in human trials, 
including reports on healthy subjects, patients and on theoretically vulnerable 
populations, such as children, elderly and pregnant women. With regard to animal data 
the main effort was devoted to understanding the translation of findings to human 
applications (e.g., the relationship of dose of the stimulation and safety). Concerning 
patients, only the most frequently investigated clinical groups were included (major 
depression, chronic pain and stroke), because of lack of data in other populations. 
Special stimulation conditions that are increasingly used during the last years, e.g., 
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combination of TES with other methods, such as stimulating patients with implants, 
combination of TES with transcranial magnetic stimulation (TMS) or functional 
magnetic resonance imaging (fMRI), as well as “do it yourself” use for neuro-
enhancement purposes, were also considered, because of the theoretical increased risk 
in these conditions. Furthermore, other stimulation settings than ‘transcranial’ in which 
recent safety data are available were also integrated, e.g., using transcutaneous spinal 
direct current stimulation (tsDCS) and optic nerve stimulation (ONS).  
In general, human studies that evaluate parameters of neuronal damage, such as 
neuron specific enolase (NSE), magnetic resonance imaging (MRI) (Nitsche et al. , 2004), 
electroencephalography (EEG), and neuropsychological tests (Iyer et al. , 2005, Tadini et 
al. , 2011) support the safety of tDCS. However, it is also important to underscore the 
fact that the safety of low intensity TES is mostly derived from an analysis of secondary 
outcomes in TES clinical trials assessing efficacy as the primary outcome. 
In this paper, we first provide an overview of the technical parameters and basic 
principles of low intensity TES used alone or combined with other methods, safety 
aspects of the stimulation with a summary of the published AEs in healthy subjects and 
different patient populations. The presumed mechanisms of TES and the efficacy of TES 
in eliciting desired outcomes are not relevant for the scope of this review except for 
instances, in which they inform about safety. Other stimulation methods that are 
applying specific (brand) waveforms or conditions, such as cranial electrical stimulation 
(CES) are also not incorporated here, but have been comprehensively reviewed by other 
authors (Mindes et al. , 2015). We also present recent regulatory issues and recommend 
rules for reporting in research and clinical practice, and finally we summarize existing 
data and provide recommendations for future safety monitoring. Consensus with regard 
to the definitions, recommendations, etc. were reached by using a modified Delphi 
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method, in this case a structured interactive communication technique (Kleymeyer, 
1976). The experts first summarized safety data related to their fields and answered 
questions in more rounds. The key results were presented and discussed in Göttingen at 
the meeting. After that the experts were encouraged to support or revise their earlier 
answers in light of the replies of other members of the panel and in response to 
reviewers’ critiques. 
 
1.1. Basic aspects: Nomenclature and explanations 
We adopt suggested definitions as already published (e.g., (Bikson et al., 2016b, 
Woods et al. , 2016a)) except that we chose the term “burden” instead of “tolerability” in 
accordance with the Declaration of Helsinki (1964) (Last revision 2013). The following 
terms are used in this paper: 
Low intensity TES: This is defined as intensities < 4 mA, a total stimulation 
duration of up to 60 minutes per day, and using ‘conventional’ electrode sizes between 1 
cm2 and 100 cm2 (delivering ≤7.2 coulombs of charge) (Bikson et al., 2016b) to apply 
frequencies between 0-10,000 Hz. The intensity of tDCS is always defined as peak-to-
baseline, while with tACS peak-to-baseline or peak-to-peak intensities can be used. The 
type of current is direct current or bipolar alternating current (Guleyupoglu et al. , 
2013). 
Safety can probably only be considered in relative terms. According to the 
definition of the European Medical Device Directive, ‘safe’ is a condition where all risks 
are accepted risks (MDD; Annex I; § I. General Requirements). However, all stimulation 
protocols carry a certain degree of risk and could cause problems in specific 
circumstances. Many problems cannot be detected until extensive research or clinical 
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experience is gained. The current approach in this field is to estimate the potential of a 
protocol becoming a hazard that could result in safety problems (e.g., using too high 
intensities or too long durations of stimulation). Hazard is a potential for an AE. Risk is a 
measure of the combination of the hazard, the likelihood of occurrence of the AE and the 
severity (Altenstetter, 2003, McAllister and Jeswiet, 2003) (See also: 
http://www.who.int/medical_devices/publications/en/MD_Regulations.pdf). The 
conclusion that a procedure is safe is based on a comprehensive and unbiased 
documentation of all AEs in relation to the frequency of application of the procedure. 
Risk must be differentiated from burden, a procedure may be burdensome (e.g., produce 
much discomfort) but nevertheless safe (e.g., not having any relevant risk for permanent 
damage).  
Generally and according to the Common Terminology Criteria for Adverse 
Events AEs (https://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-
15_QuickReference_5x7_Locked.pdf), AEs are undesirable, uncomfortable or harmful 
effects that are observed after a medical intervention that may or may not be causally 
related to it. Here, we prefer the term AE to the term Side Effect (SE), which is 
frequently employed synonymously to describe AEs. A SE should be a consequence 
different than the intended effect, and might be good or bad (beneficial or adverse). An 
example of a good side effect might be an improvement of memory by an intervention 
for depression. An AE is by definition always bad. In the context of the present paper the 
term SE will not be used in accordance with recommendations in the ICH guidelines 
(Baber, 1994, Food and Drug Administration, 2011). According to this classification, a 
mild AE (MAEs – grade 1) is defined as involving mild symptoms  for which no medical 
treatment is necessary (i.e. skin redness or tingling during TDCS) while a moderate AE 
(grade 2) indicates the need of local or noninvasive treatment (e.g., in the case of TES, 
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the local application of a cream after a skin burn). Serious AEs (grade 3) (SAE) are 
severe or medically significant but not immediately life-threatening, include the 
requirement for inpatient hospitalization or prolongation of hospitalisation. Life 
threatening SAEs include any event that may be life threatening (grade 4) or death from 
the AE (grade 5). 
Suspected Adverse Reaction (AR) means any AE for which there is a reasonable 
possibility (causality is probable, likely or certain) that the intervention caused the AE 
(Baber, 1994, Food and Drug Administration, 2011). The distinction between AE and AR 
is not always clear, first because causality often cannot be proven unambiguously, and 
second because some effects (e.g., sedation) may be in some instances good but in other 
instances bad for the patient. Another point to be considered is unexpectedness. An AE 
or suspected AE is generally considered unexpected if it is not listed in the information 
brochure or is not listed at the specificity or severity level that has been observed or it is 
not consistent with the risk information described in the investigational plan (FDA 
regulations, 21CFR312.32, safety reporting). Unexpected ARs require particular 
attention because their correlation with the procedure may be neglected. If for example, 
someone is treated and is hit by a car an hour later, this is usually not considered as AR. 
However, if it is due to sedation and cognitive impairment it may indeed be an AR. 
Corresponding to the definitions above, mild, moderate and severe ARs may be defined. 
The risk-benefit ratio is the overall ratio of all potential benefits of a procedure 
“divided by” all the ARs of a procedure. Usually, a procedure is only acceptable if the 
beneficial effects outweigh the risks. 
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2. Assumptions regarding dose-response relationship, animal studies 
TES dose is defined by all of the parameters of the stimulation device that affect 
the generated electric field (EF) in the body with units of V/m (or, equivalently, 
mV/mm) (Peterchev et al. , 2012). This includes the parameters of the electrode 
montage (skin contact area), the waveform applied to the electrodes and at the case of 
tACS, the stimulation frequency. 
The parameters delivered by the stimulation equipment are well defined and 
reproducible, while other influencing factors are not (e.g., individual tissue properties 
and anatomy, age, gender, baseline neurotransmitter concentrations, genetics, dynamic 
state of the brain before and during stimulation) or only barely controllable. 
Nevertheless, they shape the physiological responses to the stimulation and should 
therefore be considered along with the dose selection. Due to the high individual 
variability of these factors the electrical stimulation dose cannot fully determine the 
magnitude of the physiological or therapeutic outcome since it cannot be guaranteed 
that given the same doses the outcomes of stimulation will be the same. Furthermore, 
the indirect effects of TES, e.g., afferent low threshold stimulation of peripheral nerves, 
cranial nerves and retina cannot be avoided and can lead to neuromodulatory effects of 
their own or in conjunction with brain stimulation. This presents a challenge to 
researchers and clinicians when finding the ‘optimal’ dose for a given application. 
Unfortunately, due to these uncontrollable factors and additional putative mechanisms 
that are initiated during stimulation (activation of glial cells, vasodilation, changes in 
blood-barrier permeability, etc.), the current state of knowledge of the physiological 
mechanisms of TES remains limited. At present, in most studies the dose is chosen based 
on previously published data, prior clinical experience, individual measures such as 
thresholds, computational models, summary metrics (including all parameters: 
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intensity, electrode size, stimulation duration) and safety considerations based on 
human and animal experimental data.  
In vivo, the dosage induced by tDCS may, in a first approximation, be the EF as 
described by the charge density, given as (current [A] * stimulation duration [s]) / 
electrode contact size [m²]). However, the relation of this to EF or time integrated EF on 
the cortex is not simple and certainly not linear (Miranda et al. , 2009, Ruffini et al. , 
2013b). In humans, tDCS with approximately 1 mA using standard contact electrodes 
(sizes between 16-35 cm2) results in charge densities ranging from 170 to 480 C/m² 
(Liebetanz et al. , 2009). In animal experiments, much higher charge densities, 
sometimes exceeding the doses in human low intensity TES studies by several orders of 
magnitude, have been applied. In an animal study, safety limits were determined 
histologically by applying DC of increasing intensities directly to the rat cortex using an 
epicranial wet electrode (Liebetanz et al., 2009). At current densities between 14.3 and 
28.7 mA/cm2, corresponding to a charge density threshold below 52400 C/m2, no 
histologically detectable brain lesions were induced. In a histology-based (hematoxylin 
& eosin staining) study, safety limits were determined by applying increasingly powerful 
tDCS regimes through an open epicranial wet electrode (Liebetanz et al., 2009). 
Combined with updated safety data in rats, this threshold approximation obtained from 
the rat experiments was estimated to be over one order of magnitude higher compared 
to current clinical protocols (Bikson et al. , 2016a). But many uncertainties in the 
translation of animal studies to human experiments remain.  
 
3. Interaction of EF with tissue, electroporation, galvanotaxis  
A variety of montages ranging from two large, pad electrodes to arrays of smaller 
electrodes are used for tDCS (Alam et al. , 2016) with a typical current of 1-2 mA (0.03-2 
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mA/cm2 current to electrode area ratios depending on the electrode size); this results in 
cortical EF strengths of up to 0.4 to 0.8 V/m (Ruffini et al. , 2013a) with typical durations 
of 10-30 minutes. Both the applied current and the resulting brain EFs are ~1000-fold 
lower than those for pulsed stimulation used for electroconvulsive therapy (ECT) (Alam 
et al., 2016). These small EFs are considered to be below the intensity required to evoke 
action potentials in a resting cell (Radman et al. , 2009), but likely modify spontaneous 
firing rates and ongoing processes such as plasticity that are sensitive to polarization 
levels (Fritsch et al. , 2010, Jackson et al. , 2016, Ranieri et al. , 2012), and over time may 
induce molecular or structural changes. Indeed, neuronal network activity generates its 
own endogenous EFs in brain extracellular spaces and these, in turn, influence network 
firing (Frohlich and McCormick, 2010). The measured field strength in the ferret visual 
cortex was around 2 – 4 V/m and altered the neuronal transmembrane potential 
(Vmem) by 0.5 and 1.3 mV, respectively (Frohlich and McCormick, 2010).  
Many developing and regenerating tissues generate steady electrical gradients, 
and many cell types respond to these signals with directed migration, enhanced 
migration rates and regulated proliferation and differentiation. This migration is termed 
galvanotaxis and occurs at physiological field strengths of 5 – 150 mV/mm. With very 
long stimulation duration, galvanotaxis may play a role in the safety of tDCS. The 
mechanisms that drive cell migration in an EF include induced asymmetries of 
electrically charged membrane proteins and local activation of downstream signaling 
pathways, e.g., the neuronal nicotinic ACh receptor in nerve growth cones coupled to 
cAMP signaling, and the EGF receptor at the leading edge of corneal epithelial cells 
coupled to ERK1/2 and PI3K signaling (McCaig et al. , 2005). Recent additions to this 
array of molecular players include ATP and the P2Y1 receptor, which transduce the EF 
into cathodal neuronal migration. The concept involves EF-induced neuronal ATP 
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release and autocrine feedback on its own asymmetrically distributed receptors (Cao et 
al. , 2015), a concept first raised for ACh in neuronal growth cones (Erskine and McCaig, 
1995). 
The brain microenvironment modulates migration. Keratinocyte fragments 
migrate anodally and intact parent cells cathodally. Anodal migration is myosin II 
dependent, whilst the PI3kinase pathway underpins cathodal cell migration (Sun et al. , 
2013). In cytoskeletal terms, the Arp2/3 complex is required for oligodendrocyte 
precursors to migrate cathodally (Li et al. , 2015). Glioblastoma cells migrate anodally in 
2D culture, but switch to cathodal migration in 3D hyaluronic acid plus collagen cultures. 
Myosin II is not needed for the 2D anodal migration, but is required for 3D cathodal 
migration. By contrast, PI3kinase regulates the 2D anodal response (Huang et al. , 2016).   
Hypoxia enhances galvanotaxis of mouse keratinocytes, which is important in 
wound healing (Guo et al., 2015). Hypoxia is likely not to be present in the healthy brain 
but it may play a specific role in acute stroke. DC stimulation markedly increases tissue 
oxygen consumption (Pulgar, 2015), so galvanotaxis could theoretically be enhanced, or 
its threshold reduced in brain regions that are excessively stimulated by tDCS. Besides 
this, hypoxia can stimulate stem cell differentiation, and tDCS of regions containing 
neural or cancer stem cells, such as glioblastomas, may raise specific problems (Bath et 
al. , 2013, Guo et al. , 2015). However, at the present stage it is unclear if this needs 
specific considerations in terms of safety aspects, since longer stimulation durations and 
intensities higher than those applicable in human tDCS usually have be used for the 
effects reported in animal studies.  
Finally, several studies found that glia cells are involved in the mechanisms 
underlying tDCS (Gellner et al. , 2016, Monai et al. , 2016, Ruohonen and Karhu, 2012). 
Rat cortical astrocytes migrate anodally and show increased proliferation in an EF of 40 
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mV/mm (Baer et al. , 2015). Nerves and Schwann cells have a galvanotaxis threshold of 
ca. 5 mV/mm (McCaig et al., 2005), which is close to the field generated by tDCS 
(~1mV/mm). However, tDCS does not induce directed migration of labeled neural stem 
cells transplanted into the rat brain (Keuters et al. , 2015).  
At much higher EF strengths, pulses of DC stimulation have been used for 
electroporation to create nanopores in the plasma membrane to deliver 
chemotherapeutic drugs or gene therapies intracellularly, to sterilize foodstuffs and to 
ablate tumor tissue. Irreversible electroporation (IRE) uses DC short pulses of high 
voltage 3000 V and 50 A current delivered to a target volume of around 50-70 mm3. This 
gives rise to EFs of around 8000 V/m, which are about 1000 times stronger than the 
endogenous, steady DC EFs that drive galvanotaxis. IRE uses µsec pulses, is minimally 
invasive and carried out under visual control using CT or MRI imaging. Tumor ablation 
requires ~100 pulses and these are delivered between heartbeats to avoid arrhythmias. 
This non-thermal technique has also been used to ablate tumors in pancreas, lung, 
kidney, GI tract, brain, breast, cervix, prostate and sarcomas (Lu et al. , 2013, Paiella et al. 
, 2015, Ting et al. , 2016).  
 Conclusions and recommendations: Although with very long stimulation and 
much higher intensity than in currently applied approaches galvanotaxis may possibly 
play a role in tDCS, there is yet no conclusive in vivo evidence in either animal models or 
humans whether any cells close to the stimulation site have migrated away from or 
towards the electrodes, therefore, more research is needed in this field. While studies on 
electroporation have shown additive effects of pulsed DC electrical fields, the intensities 
needed for electroporation remain orders of magnitude above tDCS. However, the 
relative sensitivity of cell types (neurons, astrocytes, endothelial cells, etc.) have not 
been well studied either.  
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3.1. TES and tissue inflammation 
Inflammation in the central nervous system (CNS), i.e., neuroinflammation, is 
mediated by both brain-resident microglia and invading blood-borne immune cells. 
Neuroinflammation plays a pathophysiological role not only in classic 
neuroimmunological diseases, but also in various other neurological disorders such as 
stroke (Le Thuc et al. , 2015) and traumatic brain injury (Loane and Kumar, 2016), as 
well as in neurodegenerative diseases such as Parkinson’s disease (PD) (Tansey and 
Goldberg, 2010) and Alzheimer’s disease (AD) (Heneka et al. , 2015).  
DC fields affect the alignment and migration of various cultured immune cells 
(Pelletier and Cicchetti, 2015). Resting murine BV2 microglia cells change their 
morphology in the EF at 100 V/m and adopt an activated phenotype (Pelletier et al. , 
2015). Of note, activated BV2 microglia cells do not respond to high-voltage EFs (50-100 
V/m) in the same way as resting microglia, but rather react with a decrease in their 
viability (Pelletier et al., 2015).  
Anodal tDCS with 4 kC/m², a charge density about 10 times higher than a regular 
human dose, down-regulates inflammatory mediators in the hippocampus of rats 
subjected to chronic, stress-induced pain (Spezia Adachi et al. , 2012). Likewise, anodal 
tDCS with a charge density of 99 kC/m² – about 200 times higher than a regular human 
dose – decreases the number of activated microglia in the healthy mouse brain 
(Pikhovych et al. , 2016). In contrast, electric stimulation with a even higher charge 
densities may up-regulate inflammatory processes (Rueger et al. , 2012), suggesting that 
higher charge densities may induce subtle tissue damage and trigger an inflammatory 
response.  
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TES could enhance functional recovery after stroke and considering the 
potentially beneficial effects in the sub-acute phase after cerebral ischemia (Floel and 
Cohen, 2010), this could be consistent with the time line of post-ischemic 
neuroinflammatory processes (Dirnagl et al. , 1999). Cathodal tDSC at ~66kC/m² – 
around 200 times higher than a regular human dose – applied after focal cerebral 
ischemia in mice reduces activated microglia in the peri-infarct cortex as well as  
infiltrating mononuclear cells and neutrophils in both peri-infarct cortex and striatum 
(Peruzzotti-Jametti et al. , 2013). Multi-session cathodal tDCS applied for ten consecutive 
days after stroke in the rat accelerates recovery of function and a shift in microglia 
polarization (Braun et al. , 2016). However, all of these studies were conducted in young 
rodents in contrast to the older human stroke population. Moreover, chronic 
neuroinflammatory processes may go on for even 6-12 months or longer after a stroke 
(Walberer et al. , 2014).  
Conclusions and recommendations: Current data suggest that both anti-
inflammatory and pro-inflammatory effects of TES depend on pre-existing inflammation 
and TES current density. TES seems to not only affect activation levels of brain-resident 
and invading immune cells, but also alter their specific phenotype and polarization. 
However, current research in animals used between 4 and 200 kC/m² charge densities, 
which is about 10-500 times higher than levels of tDCS given in humans so far 
(Liebetanz et al., 2009). For currently applied protocols, there are no hints for 
neurinflammations in human studies. So far, tDCS studies did not intend to address long-
term chronic neuroinflammatory processes, but rather focused on transient 
neuroinflammatory response, such as occurring in the sub-acute phase after stroke, or 
were geared toward promoting neuroplastic processes or cortical excitability changes. 
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More research is needed in this field and the interpretation in term of “changes in 
neuroinflammation” should be treated with caution. 
 
4. Modeling (heating, induced voltages) 
Computational models of current flow relate tDCS surface dose with subject-
specific brain current density (Peterchev et al., 2012, Ruffini et al. , 2014, Truong et al. , 
2013). The precision of the prediction depends on the accuracy of the model (not simply 
the complexity; (Bikson and Datta, 2012). For a given electrode montage, increasing the 
current results in a proportional increase in the EF throughout the head – such that, for 
any given montage, 2 mA will produce an EF in each brain region double that with 1 mA. 
The local tissue current density is equal to the EF multiplied by the tissue’s conductivity, 
and thus follows the above dose-response rule for the EF. Because current density is 
predicted to be much higher in the skin than in the brain, and assuming equal sensitivity 
to injury of skin and brain, lack of skin injury may indirectly support the claim that the 
brain current flow is safe (Bikson et al., 2016b, Faria et al. , 2011, Saturnino et al. , 2015). 
All models predict that the EF in the cortex is strongly affected by the complex 
arrangement of its folds and by the electrode montage (e.g., (Datta et al. , 2009a, Miranda 
et al. , 2013, Opitz et al. , 2015b, Parazzini et al. , 2011, Sadleir et al. , 2010, Salvador et al. 
, 2010, Wagner et al. , 2014a)). The EF generally decreases with distance from the 
electrodes but is non-uniform, with hotspots on the crowns of the gyri that lie between 
and close to the electrodes, and at the bottom of sulci under the electrodes (Fig.1.).  
Computational approaches are available to calculate maximal current densities in 
any area in the brain with a defined stimulation parameter space (Bortoletto et al. , 
2016, Lee et al. , 2016, Seibt et al. , 2015, Wagner S et al. , 2016). 
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Changes in individual EF distribution can also be calculated in the presence of 
skull defects or skull plates (Datta et al. , 2010), in stroke patients with large defects 
filled by CSF (Datta et al. , 2011) and in children with thinner skulls (Gillick et al. , 2014, 
Kessler et al. , 2013, Parazzini et al. , 2015). For typical bipolar montages, and in the 
absence of skull defects or brain lesions, the values predicted for the maximum EF 
strength in the cortex of realistic head models often fall between 0.2 and 0.5 V/m using 1 
mA (e.g., (Datta et al., 2009a, Metwally et al. , 2015, Miranda et al., 2013, Parazzini et al. , 
2016, Rampersad et al. , 2014, Saturnino et al., 2015, Shahid et al. , 2013)). The maximal 
value so far reported by some investigators in a normal brain is 1.6 V/m and can be 
attributed to the conductivity values used in this particular model (Parazzini et al., 
2011). Anatomical variations can have a substantial impact on field strength (Datta et al. 
, 2012, Kessler et al., 2013, Laakso et al. , 2015, Truong et al., 2013) and may lead to 
variations by a factor of 2 or more for a fixed stimulation intensity. Predicted EF 
strengths of about 0.4 V/m in the cortex are in good agreement with data obtained in 
epilepsy patients with EF strengths of 0.6 to 1.6 V/m per 1 mA (Dymond et al. , 1975), 
and ≤ 0.5 V/m per 1 mA (Opitz et al. , 2016). These EFs may be sufficient to modulate 
neuronal network activity in hippocampal slices (~0.3 V/m (Francis et al. , 2003)), or to 
induce entrainment at low frequencies in neocortical slices (~0.7 V/m (Anastassiou et 
al. , 2011)). They are slightly lower than the endogenous EFs measured in the ferret’s 
neocortex (~3 V/m (Frohlich and McCormick, 2010)).  
The EF strength and its spatial distribution in tACS are expected to be similar to 
that observed with tDCS. It remains unclear whether the high electric permittivity of 
brain tissues can significantly affect the strength of the EF in the brain and shift the 
phase of the sinusoidal waves, in particular with higher frequencies (Logothetis et al. , 
2007, Opitz et al., 2016, Wagner et al. , 2014b). Montages with (multiple) small 
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electrodes do not affect the maximal V/m range with respect to safety considerations 
(Dmochowski et al. , 2011, Dmochowski et al. , 2013, Edwards et al. , 2013, Ruffini et al., 
2014, Sadleir et al. , 2012). Because electric current is conducted about 10 times better 
tangentially along a fiber than perpendicular to it, computational models can take fiber 
orientation into account by calculating on the basis of diffusion tensor image data in the 
MRI (e.g., free shareware www.simnibs.de) (Metwally et al. , 2012, Opitz et al. , 2015a, 
Shahid et al., 2013, Shahid et al. , 2014).  
Heating of the brain during tDCS is considered to be insignificant. For a current of 
1 mA, and assuming an EF strength of 0.5 V/m and a conductivity of 0.4 S/m, the power 
dissipated in the cortex would be about 0.1 mW/kg, which is 5 orders of magnitude less 
than the metabolic heat production rate in the brain, which is about 11 W/kg (Nelson 
and Nunneley, 1998). Assuming that the resistance of the extracranial tissue between 
the two electrodes is about 300 Ω, then the total power dissipated in the whole head 
would be 0.3 mW. In practice, the resistance between the two electrodes is more likely 
to be around 10 kΩ due to the contact impedance at the electrode-skin interfaces. In this 
case, the total power would be 10 mW, dissipated almost entirely in the scalp under the 
electrode edges. In agreement with these considerations, Datta et al. (Datta et al. , 
2009b) predicts no significant temperature increase (ΔT < 0.003 ᵒC) in the brain or in 
the scalp for conventional or multichannel tDCS montage for current intensities 
currently employed. Using multichannel tDCS, several brain regions are targeted in 
parallel using e.g., arrays of small electrodes on the scalp.  
Conclusions and recommendations: Current flow calculation models allow a 
reasonable estimation of the electric field and current density, including in deep brain 
areas. Models also allow the design of new montages including electrode arrays. 
Therefore, EF modeling for targeting predefined areas for stimulation can be helpful. 
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The main potential strength of modeling lies in subject-specific current optimization, 
which may lead to more reproducible results across individuals and increased safety.  
 
5. Electrode design for TES 
A bipolar electrode configuration is the minimal requirement and customarily 
used for tDCS, with one target electrode placed over the site of the desired cortical 
stimulation and one remote “return” electrode (but see: (Bikson et al. , 2010)). The 
return electrode may be placed on the scalp (the most frequently used site), 
concentrically around the target electrode (Laplacian montage) (Bortoletto et al., 2016, 
Datta et al., 2009a), extracephalically (e.g. (Moliadze et al. , 2010, Schambra et al. , 
2011)) or distributed over several sites (Faria et al. , 2009). 
These electrodes are typically made of conducting materials, some using plastic 
such as conductive (filled) silicone, while others are metal, usually non-polarizable 
silver/silver chloride (Ag/AgCl) (Faria et al. , 2012, Minhas et al. , 2010). The size of the 
electrode contact area (which for tDCS/tACS is defined as the electrolyte/skin interface) 
ranges between about 1 cm2 and up to about 100 cm2 (Bortoletto et al., 2016, Ho et al. , 
2016, Kronberg and Bikson, 2012, Nitsche et al. , 2007a). Target and return electrode 
may be differentiated by size and thus current density, but for bipolar montages the 
total current is equal across electrodes. Neurophysiological studies indicate that smaller 
electrodes produce more targeted outcomes while larger electrodes decrease the 
current density below a given stimulation threshold, such that tDCS no longer has a 
physiological effect (Nitsche et al., 2007a). Imaging and modeling suggest that electrode 
placement may play a more significant role than size (Faria et al., 2011) (Antal et al. , 
2014).  
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A recent study has compared scalp sensations using the classical bipolar and HD-
tDCS montages over the prefrontal cortex using 1 mA for 20 min (Hill et al. , 2017). 
Stronger sensations were reported after 5 minutes of stimulation with HD-tDCS 
compared to either bipolar tDCS or sham tDCS, and this is likely due to the higher 
current densities produced with this montage using smaller electrodes. After 15 min of 
stimulation, sensations did not differ between the three conditions and participants 
were not able to guess at a level better than chance, which type of stimulation they had 
received.  
Conclusions and recommendations: A multitude of possible electrode 
placements, using either bipolar montage or arrays, permit shaping current flow 
patterns through the head or targeted stimulation of cortical areas. From available data, 
no specific safety issues apply for different electrode designs used in tDCS studies. There 
is no evidence for brain injury following conventional tDCS and multichannel-tDCS 
protocols. The low to moderate scalp sensation ratings documented in these studies 
indicate a good overall level of stimulation tolerability provided proper electrode design, 
preparation, and conventional dose guidance are followed (Woods et al., 2016a). For 
extended protocols (higher intensities, longer duration), a rationale should be given, and 
it would be advantageous to gather safety information systematically for these protocols 
before extensive human applications (Bikson et al., 2016b).  
 
5.1. Electrochemistry of electrodes 
The electrode acts as a transducer between the electron currents in the technical 
system (stimulator) and the ion currents in the biological system (body). Current can be 
transmitted across the electrode/electrolyte interface by capacitive charging of the 
Helmholtz double layer or by electrochemical (faradaic) reactions (Cogan, 2008). Even 
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with large electrodes and thus very low charge densities, one cannot inject a DC of 1-2 
mA over a period of several minutes by capacitive charging alone. For instance, the 
Helmholtz double layer of a 6 cm2 electrode has a capacitance of ca. 120 µF (Kronberg 
and Bikson, 2012). To charge such a capacitance with a constant current of 1 mA for 15 
min would require a voltage of up to 7500 V (1 mA*15 min/120 µF). The Helmholtz 
double layer reaction is not associated with any transfer of charge carriers across the 
interface, but results in an increase in the electrode potential (overpotential), which may 
cause the onset of unwanted electrochemical reactions such as gas formation by 
hydrolysis. This is of importance in implanted systems such as cochlear or retinal 
implants, where the net electrochemical reactions at the electrode interface must be 
kept at an absolute minimum in order to avoid hydrolysis and electrode corrosion 
(Merrill et al. , 2005). For this reason, invasive neural stimulation is usually performed 
with very short (60-1000 µs (Howell et al. , 2015)), charge-balanced, biphasic pulses, in 
which a cathodic pulse that induces the desired neural stimulation is followed by an 
anodic pulse to reverse the electrochemical reactions. The charge injection capacity is 
defined as the maximum charge per pulse and electrode area that can be “safely” 
injected with an electrode without inducing irreversible electrochemical reactions that 
would cause electrode corrosion and/or tissue damage. It is mainly dependent on the 
electrode material and can reach values of several mC/cm2 for materials such as iridium 
oxide or conductive polymers (Cogan, 2008). Since the capacitive charging is limited to 
about 20 µF/cm2 (Merrill et al., 2005), and since in transcranial stimulation larger 
current densities are usually required, capacitive charging of the Helmholtz double layer 
does not play a major role.  
Biphasic sinusoidal pulse currents are mostly used for tACS. Due to the large 
electrode areas in transcranial applications, the applied charge densities are low (<100 
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µA/cm2), resulting in an injected charge density of less than 1 µC/cm2 per phase (Woods 
et al. , 2016b). No irreversible electrochemical products are known to accumulate at the 
electrode with such low current densities, although the effective phase (“pulse”) 
duration during low-frequency tACS (e.g., 1 Hz tACS has a 500 mS phase duration) is 
much longer and increases the possibility of irreversible reactions. Sinusoidal 
stimulation is thus not used for implants. The electrodes used for tACS are adapted from 
tDCS and, hence, provide the same compensation for any potential electrochemical 
changes. tRNS is not considered here in detail but the use of high-rate charge-balanced 
pulsing would minimize concerns about electrochemical changes (Merrill et al., 2005), 
and tRNS seems relatively well tolerated by subjects (Ambrus et al. , 2010, Curado et al. , 
2016, Terney et al. , 2008). 
In the case of tDCS, current across the interface is unidirectional, of course, and 
neural stimulation paradigms such as the above mentioned charge injection capacity 
(Cogan, 2008, Merrill et al., 2005) can therefore not be safely transferred directly to this 
type of stimulation. The use of DC for stimulation does not allow for reversal of 
electrochemical reactions during stimulation, but effects such as corrosion and 
hydrolysis at the electrode may not have as severe consequences for the patient as with 
implantable stimulators. The essential aspect of electrodes used for tDCS (and tACS) is 
that metal or conductive rubber where electrochemical reactions may occur are not 
placed directly on the skin; an electrolyte (saline of gel) always separates the two.  
(Minhas et al., 2010). Therefore, in TES, the current is mainly injected by faradaic 
reactions but the products of these reactions are kept away from the skin. Conductive 
rubber electrodes are convenient for macro tDCS/tACS as they are flexible and can be 
inserted into a saline soaked sponge “pocket”. As an alternative, especially when smaller 
electrodes are used (e.g., for multichannel stimulation), Ag/AgCl electrodes are well 
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suited due to their non-polarizable character, i.e., their low faradaic resistance results in 
almost no capacitive charging of the double layer (Merrill et al., 2005). This keeps the 
electrode potential constant, preventing unwanted faradaic reactions such as gas 
formation. The reaction mainly responsible for charge transmission at the Ag/AgCl 
electrode is the formation of AgCl by dissolution and oxidation of solid silver at the 
anode, and the formation of solid silver by decomposition of AgCl along with a reduction 
of silver ions at the cathode (Merrill et al., 2005, Minhas et al., 2010). The formation of 
AgCl requires a sufficient amount of free chloride ions in the vicinity of the electrode, 
which is provided by the electrode gel applied between the electrode and the skin. For 
this reason, electrode gels containing Cl– ions are typically used with Ag/AgCl 
electrodes.  
Small Ag/AgCl electrodes (1 – 3 cm2, 1-2 mA) with electrode gel, typically 
containing salts, such as sodium chloride or potassium chloride, are being used more 
frequently for tDCS with no AEs (e.g. (Borckardt et al. , 2012, Faria et al., 2012, Murray et 
al. , 2015)). Twenty minutes of real (n = 13) or sham (n = 11) 2 mA HD-tDCS over the 
motor cortex using 1 cm2 electrodes (Borckardt et al., 2012) or 3 x 20 min sessions with 
1-2 mA using 3 cm2 PiStim electrodes (hybrid Ag/AgCl EEG/tDCS electrodes with a 
circular contact area Starstim, Neuroelectrics) (Murray et al., 2015) resulted in no AEs.  
For the sponge electrode design the function of the sponge is to fix the conductive 
rubber away from the skin and contain the saline. The salinity is important (Dundas et 
al. , 2007a), and gel can be substituted for saline. When using a paste electrolyte the 
sponges may not be necessary but then extreme care must be taken to ensure the 
conductive rubber does not accidently push through and contact the skin. For HD 
designs, a holder fixes the distance between the Ag/AgCl electrode and the skin, and also 
holds the gel. The composition of the electrolyte (saline, gel, or paste) is important as it 
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influence the uniformities of current flow through the skin as well as acting as a 
chemical (diffusion) buffer between changes at the surface of the metal/rubber and skin  
(Dundas et al., 2007a, Kronberg and Bikson, 2012, Minhas et al., 2010). For both sponge-
based Ag/AgCl electrodes the materials and shapes of electrode assembly are thus 
critical for burden (Minhas et al., 2010). Equally important is adherence to established 
protocols for electrode preparation and application (Woods et al., 2016a). 
Recommendations: Use either sponge-like electrodes soaked in saline solution 
that contain an electrode pad made of conductive rubber (filled silicone), or Ag/AgCl 
electrodes with appropriate cream. Tap water is not recommended, and care should be 
taken, even when using saline solution in longer lasting experiments as increased 
contact resistance may also arise from drying of the sponges (Woods et al., 2016b). In 
such cases an electrode gel or cream is a possible alternative. Abrading the skin (scalp) 
before electrode placement is not recommended (Loo et al. , 2011).  
 
6.  The application of low intensity TES in human studies: AEs in human 
studies 
6.1. Historical background of electrical stimulation 
The history of electric stimulation starts with the application of electricity 
generated by electric fish, which are able to generate 2 ms long pulses, up to 600 V and 
up to 1 ampere. Because the purpose of this feature is to stun prey, electric fish are 
unsafe by design. Immediately after the invention of the voltaic pile around 1800, 
several books were published on the use of the pile in a variety of mostly neurological 
diseases (Althaus, 1860, Augustin, 1801, Grappengiesser, 1801, Hellwag and Jacobi, 
1802, Kluge, 1811, Ziemssen, 1864). Due to unknown details in the chemical 
composition and construction of the voltaic piles, it is almost impossible to determine 
which intensities were used at that time. In addition, AEs were not documented 
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systematically in these early studies, and most of the reported AEs referred to 
stimulation of peripheral nerves (Table 1). Thus, they will not be considered in the 
present context. This also applies to electrostimulation techniques for 
electroanaesthesia and electrosleep originally developed in Russia and summarized 
partially by Guleyupoglu and his coworkers (Guleyupoglu et al., 2013). Major known AEs 
associated with TES in humans (healthy and clinical populations) published between 
2000 and 2016 are summarized in Tables 2 - 8. 
 
6.2. Local pain, headache, discomfort 
The first evaluation of tDCS-induced AEs summarized data from approximately 
500 healthy subjects between 2000 and 2003 (Nitsche et al. , 2003). In most of the 
studies a 5 x 7 cm stimulation electrode was positioned over M1 and the return 
electrode positioned over the contralateral supraorbital area. Weak direct currents (1 
mA; current density 0.029 mA/cm2) were applied for up to 20 minutes. Typical events 
were slight transient tingling sensations under the electrodes or light flashes when the 
stimulation was switched on or off abruptly. In an evaluation of 103 healthy volunteers 
with currents of 1 mA or 2 mA (current densities 0.04 and 0.08 mA/cm2) applied for up 
to 20 minutes with the stimulus electrode over the prefrontal cortex and the return 
electrode over the contralateral supraorbital area, only a transient erythema was seen 
under the stimulus electrode in two subjects (Iyer et al., 2005). It was suggested that this 
might be related to local vasodilatation (Guarienti et al. , 2015). Nevertheless, it is still 
unknown why vasodilatation under the anode is often different than under the cathode. 
Possible mechanisms include pH changes in different directions depending on 
stimulation polarity (Almalty et al. , 2013, Ezquerro et al. , 2017, Minhas et al., 2010).  
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The AEs seen in 567 tDCS sessions (1 mA; 9 to 15 min; current density 0.029 
mA/cm2; electrode placement occipital, temporal or parietal; motor or non-motor 
cortex) in 102 subjects (77 healthy volunteers and 25 patients with migraine, post-
stroke, or tinnitus) were mild tingling sensation (70.6%), moderate fatigue (35.3%), 
slight itch under the stimulus electrode (30.4%), headache (11.8%), nausea (2.9%) and 
insomnia (0.98%) (Poreisz et al. , 2007). The incidence of AEs, all belonging to the class 
of MAEs, such as transient headache was consistently lower after tDCS than after rTMS 
(11.8% vs. 23% in rTMS) (Machii et al. , 2006, Rossi et al. , 2009, Rossini et al. , 2015). 
A review of 209 tDCS studies (Brunoni et al. , 2011a) described the primary MAEs as 
itching (active vs. sham tDCS group: 39.3% vs. 32.9%), tingling (22.2% vs. 18.3%), 
headache (14.8% vs. 16.2%), burning sensations (8.7% vs. 10%) and discomfort (10.4% 
vs. 13.4%), with no significant differences between active and control groups. The latter 
received only a short stimulation at the beginning of the treatment session. However, in 
a prospective comparison of active and sham tDCS in 131 subjects (277 tDCS sessions 
with the standard protocol using 1-2 mA stimulation intensity) (Kessler et al. , 2012) 
found a statistically significant higher incidence of MAEs in the active stimulation group 
as compared to the sham group with tingling (89 % versus 53 %), itching (81 % versus 
42 %), burning sensation (65 % versus 33 %), pain (31 % versus 11 %) and headache 
(15 % versus 9 %). Also, as expected, the incidence of AEs in the prospective study was 
higher than that in a retrospective study (Kessler et al., 2012).  
Repeated daily tDCS (up to five sessions), mostly with sponge electrodes, with a 
current density of about 0.06 mA/cm2 (i.e., electrodes 25–35 cm2, currents 1.5–2.1 mA) 
caused persisting skin lesions under the electrodes in some subjects, typically on the 
forehead or over frontal cortical areas (Frank et al. , 2010, Nitsche et al. , 2008, Palm et 
al. , 2008b, Riedel et al. , 2012, Rodriguez et al. , 2014, Wang et al. , 2015b) (Table 2). 
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Vitiligo does not seem to increase the risk (Shiozawa et al. , 2013). Contact dermatitis 
following tDCS has also been reported (Riedel et al., 2012). Contributing factors are 
electrode position, pre-existing conditions such as allergies to skin creams, extensive 
skin heating, high impedance (electrode dry or defect, solution salinity of electrode 
sponges and deterioration of the sponges, inappropriate contact solution, incorrect 
electrode fixation, non-uniform contact pressure of electrodes to skin), prolonged 
duration or repeated sessions, high current density (high current, small electrode) 
(Dundas et al. , 2007b, Frank et al., 2010, Guleyupoglu et al. , 2014, McFadden et al. , 
2011, Norris et al. , 2010, Palm et al. , 2014, Palm et al. , 2008a, Riedel et al., 2012, 
Rodriguez et al., 2014, Turi et al. , 2014, Wang et al., 2015b).  
Conclusions and recommendations: Minimizing skin reactions due to active 
stimulation is an readily realizable but important consideration in the management of 
the treatment. Irritation can be prevented by best possible preparation of skin and 
stimulation electrode. Abrading the skin before the fixation of the electrode is not 
recommended, only light cleaning with a pad, if it is necessary (Loo et al., 2011). The 
application of the stimulation over non-homogenous (e.g., scars) or inflamed skin areas 
should be avoided. To minimize serious skin damage, investigators need to pay close 
attention to electrode application, and participants should be instructed to report 
discomfort immediately, particularly when higher intensities are used. 
 
6.3. Perceptual and cognitive AEs  
No obvious individual AEs in either perceptual or cognitive domains causing 
changes (impairment) in performance on neurocognitive tests have been reported 
following TES. At the perceptual level, undesired online secondary effects are related to 
the protocol used. tACS with frequencies of 8-40 Hz and currents above 1 mA, as well as 
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tDCS that it is not ramped up and down in the initial and final seconds of stimulation are 
likely to induce phosphenes, depending on the distance of the electrode to the eye, and 
tingling sensations under the electrode during stimulation (Fertonani et al. , 2015, Turi 
et al. , 2013). Depending on TES intensity phosphenes can significantly interfere with 
visual perception (Schwiedrzik, 2009). 
Almost all reported cognitive effects in controlled studies were related to the 
primary or secondary study target, and hence were more physiological reactions than 
AEs. They are associated with specific stimulation effects, either in down-regulating and 
up-regulating cortical states or degrading the signal-to-noise ratio that can impair or 
improve performance (e.g., (Macher et al. , 2014, Mathys et al. , 2010, Peters et al. , 2013, 
Plewnia et al. , 2013, Rogalewski et al. , 2004, Zwissler et al. , 2014)). This implies 
changes in neuronal activity that continue beyond stimulation and rely on mechanisms 
comprising inhibitory homeostasis of the system, long-term depression and 
metaplasticity (Muller-Dahlhaus and Ziemann, 2015). 
The reported cognitive “AEs” of TES may not capture all effects. It is impossible to 
quantify all aspects of cognition at one time during TES, only the functions tested can be 
quantified. TES-induced improvement in one function may be associated with the 
simultaneous decline of another cognitive function (Iuculano and Cohen Kadosh, 2013, 
Younger et al. , 2016). In this context a zero-sum model has been proposed claiming that 
every gain in cognitive functioning is necessarily accompanied by a loss in some other 
domain (Brem et al. , 2014b, Fertonani and Miniussi, 2016, Luber, 2014).  
Conclusion: TES does not appear to cause apparent perceptual or cognitive AEs 
effects in healthy subjects.    
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6.3.1. Neuroenhancement 
Neuroenhancement can be defined as any augmentation of core information 
processing systems in the brain apart from natural training, including the mechanisms 
underlying perception, attention, conceptualization, memory, reasoning and motor 
performance. Pharmacological neuroenhancement refers to the use of substances or 
devices by healthy subjects with the purpose of cognitive enhancement, e.g., of vigilance, 
concentration, memory, or mood. "Brain doping" raises numerous ethical and social 
concerns. In particular, liberalization demands are continuously being discussed 
(Franke and Lieb, 2010). Almost every TES method has been proposed for 
neuroenhancement. Theories behind a potential neuroenhancement include the 
following mechanisms: 
1) Balance effect: Balance effects are based on the model of inter-hemispheric rivalry 
between homologue areas. They have been investigated particularly for complex 
motor- and space-related functions in healthy subjects and patients. Inter-
hemispheric balance effects have been used to account for the paradoxical 
enhancement of ipsilateral motor function, ipsilateral visuospatial attention, or 
lateralized verbal memory and language abilities, when using brain stimulation to 
suppress activity in specific cortical regions. 
2) Entrainment theory: The entrainment theory is based on the notion that oscillatory 
activity in brain networks is associated and causally related to specific functions. 
According to this model, stimulation mimics brain oscillations and has an effect by 
entraining the brain’s natural state. For instance, applying tACS during sleep 
promoted lucid dreaming at specific frequencies of 25 and 40 Hz with a concomitant 
increase of 25 and 40 Hz EEG activity (Voss et al. , 2014).  
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3) Stochastic resonance: Stochastic resonance refers to the notion that injection of 
subthreshold noise into a system can serve to enhance signal detection (Fertonani 
and Miniussi, 2016, Stacey and Durand, 2000, van der Groen and Wenderoth, 2016).  
4) Net zero-sum framework: Applied to the brain, this model suggests a situation 
whereby neural “gains” must be matched by neural “losses”. Accordingly, if 
stimulation induces a “facilitation”, a detrimental opposite effect should occur 
somewhere else in the brain (Brem et al. , 2014a).  
Single or repetitive studies have claimed an improvement of a given cognitive 
function following brain stimulation sessions. The reported motor and cognitive 
(attention, risk-taking, planning and deceptive abilities) enhancements in healthy 
volunteers were described as follows: DLPFC - attention, risk-taking/impulsivity, 
planning and deceptive abilities; IFC: Inferior Frontal Cortex - attention and deceptive 
abilities; PPC: Posterior Parietal Cortex - attention; M1: motor cortex – reaction time, 
motor learning; TPJ: temporoparietal junction - working memory. However, appropriate 
control conditions were frequently lacking, in particular the real stimulation of a non-
target area in order to prove site-specificity as compared to generalized and non-specific 
mechanisms related, for example, to increasing alertness/vigilance. 
Altogether, the conclusions from a previous study by Bikson et al (Bikson et al. , 
2013) seem appropriate: “…Controlled investigation of tDCS for treating neuropsychiatric 
disorders or for neurorehabilitation should not be confused with improvised devices or 
practices that apply electricity to the brain without reference to established protocols. 
...Experimentation outside established and tested norms may put subjects at risk. 
…Meddling with the tDCS dose is potentially as dangerous as tampering with a drug’s 
chemical composition. Painstaking efforts by researchers to understand the risks and 
benefits of tDCS should never be interpreted as encouraging such practices.” 
38 
 
 
6.4. Safety of tACS  
Sensations under the electrodes are generally less intense during tACS than 
during tDCS (Fertonani et al., 2015). This may in part be due to less intense 
electrochemical effects, and one might speculate that cell membranes of sensory 
neurons act as low-pass filters (Deans et al. , 2007) and are thus less susceptible to high-
frequency signals. Skin sensations and phosphenes are strongest with frequencies 
between 10 and 30 Hz with a peak at 20 Hz and diminish at higher and lower 
frequencies (Turi et al., 2013). The most pronounced phosphenes were seen with frontal 
electrode montages and the most intense skin sensations with central montages; both 
phosphenes and skin sensations increased with stimulation intensity. Similarly, 
dizziness appeared to (non-significantly) increase with stimulation intensity (Raco et al. 
, 2014). No pathological changes in EEG or anatomical MRI, and no increase in NSE-
levels were observed after tACS at 5 kHz with 1 mA applied for ten minutes (Chaieb et al. 
, 2011, Chaieb et al. , 2014). 
The highest stimulation intensity applied to date in a human study was 
administered using an electrical current theta-burst protocol (ecTBS) (Kunz et al, in 
press). Using the same design as Huang et al (Huang et al. , 2005), the authors applied 
three altered ecTBS protocols: 5 mA ecTBS with sinusoidal bursts of 5 ms duration, 10 
mA ecTBS with sinusoidal bursts of 1 ms and 10 mA ecTBS with sinusoidal bursts of 5 
ms, using a 5 kHz carrier frequency in order to avoid or at least minimize skin pain as 
known from high pulse electric stimulation and to achieve greater field strengths. Six of 
the 17 subjects reported MAEs after stimulation, mainly headache. In another study 
during a combined stimulation with tDCS and 60 Hz tACS (ratio 2:1) using a stimulation 
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intensity of 5 mA administered for 35 min, the stimulation was well tolerated with one 
patient (out of twenty) reporting a post-stimulation headache lasting 15 min 
(Nekhendzy et al. , 2010).  
The longest tACS stimulation duration applied to date in humans in the course of 
one day was 45 +/- 10 min of 1.5 mA at 40, 60, and 80 Hz (Laczo et al. , 2012). None of 
the sessions had to be interrupted because of AEs; two of the 20 subjects complained of 
a mild post-stimulation headache.  
The longest stimulation duration over several days was applied to healthy 
volunteers using 1.5 mA at their individual alpha frequency for twenty minutes per day 
on five consecutive days. No AEs were reported (Muller et al. , 2015). The subjects were 
unable to determine whether they had been assigned to the stimulation or the sham 
group. The sham group received a short stimulation at the beginning of the session. 
Electrophysiological assessment methods, such as EEG or 
magnetoencephalography (MEG), can be used sequentially or simultaneously (provided 
detailed attention to potential artifact; (Noury et al. , 2016))to monitor the effects and 
efficacy of tACS on brain activity (Antal et al. , 2008a, Zaehle et al. , 2010) similarly to 
tDCS (Cunillera et al. , 2016, Faria et al., 2012, Luft et al. , 2014, Mancini et al. , 2015). 
Recording electrophysiological data during stimulation requires methods for artifact 
elimination (Helfrich et al. , 2014, Neuling et al. , 2015). Manufacturers need to ensure 
that tACS and EEG/MEG devices can be safely operated together.  
Conclusions and recommendations: There is consensus it is safe to apply tACS 
at the intensities and durations tested in published experimental protocols in healthy 
populations. When tACS is combined with EEG or MEG, one must prevent conductive 
fluids between electrodes in order to avoid short circuiting adjacent electrodes and, in 
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this regard, electrode gel is preferable to saline solution (Helfrich et al., 2014). Similarly 
to previously published tDCS-EEG studies, no AEs have been reported for this 
combination other than those seen in tACS without additional electrophysiological 
monitoring. 
 
6.5. Safety of combinations of TES with evaluation methods in clinical 
neurophysiology 
6.5.1. Combined TES and rTMS 
Theoretically, priming with tDCS might intensify the AEs of subsequent repetitive 
TMS (rTMS) (cf. (Rossi et al., 2009)). Studies combining TES with rTMS in healthy 
subjects reported no AEs during and after the combined interventions (see Table 3) 
(Karabanov et al. , 2015, Muller-Dahlhaus and Ziemann, 2015). Similarly, no AEs were 
reported in any of the reviewed small clinical studies applying a combination of tDCS 
and rTMS (see Table 4), apart from increased scalp pain with rTMS when preceded by 
tDCS in one pilot study (Loo et al. , 2009). In summary, there is currently no evidence 
that the combination of tDCS and rTMS is unsafe or is associated with burden. 
 
6.5.2. tDCS in MRI 
MR-compatible stimulation devices allow functional MRI and magnetic resonance 
spectroscopy (MRS) with only minor effects on image quality (Antal et al. , 2011b, 
Gbadeyan et al. , 2016, Woods et al., 2016b) predominantly in 3-tesla MR systems, but 
also without noticeable problems in 7-tesla fields (Barron et al. , 2016). Neuroimaging 
studies with tDCS before (Baudewig et al. , 2001, Lang et al. , 2005, Stagg et al. , 2009) or 
during neuroimaging (Antal et al., 2011b, Hone-Blanchet et al. , 2015, Rae et al. , 2013, 
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Stagg et al. , 2013) or combined with magnetic resonance electrical impedance 
tomography (Kwon et al. , 2016) reported no AEs.  
Specific safety precautions do apply. The study protocol must always comply with 
the safety standards for both tDCS and MRI. As for all metal containing devices, the tDCS 
stimulator MUST ALWAYS remain outside the MR cabin to avoid the stimulator coming 
too close to the static magnetic field. The stimulator is connected to the MR-compatible 
electrodes by specially designed, MR-compatible (non-ferrous or appropriately shielded 
and radiotranslucent) leads. In some devices the stimulating leads are passed through a 
radio-frequency filter tube in the MR cabin wall and through a radiofrequency filter 
module, consisting of two filter boxes (Antal et al., 2011b). In other devices (see: 
http://wiki.neuroelectrics.com/images/c/c5/NEWP201505-MRI_tCS_compatibility.pdf) 
there is only one filter attached to the patch panel of the MRI machine to ensure that the 
filtered currents flow through the ground and to ensure that the faraday cage of the MRI 
room is not opened and there is no noise during normal MRI image acquisition.  
The filter module is necessary to suppress the radio-frequency noise that is 
brought into the scanner room via the stimulating leads. If tDCS is applied with the 
subject in the MR bore, the radio-frequency pulses generated by the MR may induce 
eddy currents in the stimulation leads, causing heating of the leads with the risk of skin 
burns. Each lead must therefore be fitted with protective, high-ohmic resistors (ca. 5 
kOhm) and the leads should always run parallel to the axis of the scanner bore without 
forming any loops (Meinzer et al. , 2014a, Woods et al., 2016b). Unshielded cables inside 
the MRI room should be as short as possible to avoid crossing wires and loops that 
might induce current to the patient. Longer cables should be designed for the MRI room 
and therefore shielded. 
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For tDCS in the MR cabin, biocarbon electrodes and thick layers of electrical 
conductance paste should be used rather than saline-soaked sponges or low viscosity 
electrode gel. The reason for this is that tDCS-MRI experiments may take longer and 
electrodes cannot easily be accessed in the scanner to prevent the electrodes from 
drying with the associated risk of thermal injury (Woods et al., 2016b).  
In contrast to tDCS, tACS is less likely to cause artifacts (Antal et al., 2014). No AEs 
other than those with tACS alone have been reported for this combination (Alekseichuk 
et al. , 2015, Cabral-Calderin et al. , 2016, Vosskuhl et al. , 2015).  
 
6.6. Optic nerve stimulation  
Animal studies apply crush and transection models of the optic nerve in order to 
investigate new treatment options for glaucoma and other optic neuropathies, such as 
electrical optic nerve stimulation (eONS) (Fu et al. , 2015). The studies indicate that 
eONS may induce structural neurorestoration (axonal regeneration), functional 
neurorestoration (visual evoked potentials), and neuroprotection (survival of ganglion 
cells) (Miyake et al. , 2007, Morimoto et al. , 2005, Tagami et al. , 2009, Yin et al. , 2016) 
which are assumed to be mediated by release of neurotrophic factors and increased 
chorioretinal blood flow (Fu et al., 2015). ONS can be achieved with many frequencies; 
the sensitivity peaks around 15 Hz (e.g. (Brindley, 1955)). One proprietary approach 
(EBS technologies GmbH) sets the stimulus frequency between the individual’s EEG  
frequency and his flicker fusion frequency. This is applied on ten consecutive days with 
each session lasting approx. 60 to 90 min (Gall et al. , 2016). To date, 760 patients with 
optic neuropathies, e.g., following stroke or with postchiasmatic lesions, have been 
treated in various clinical trials using this technology (Fedorov et al. , 2011, Gall et al. , 
2013, Gall et al. , 2010, Gall et al., 2016, Gall et al. , 2011, Gall et al. , 2015, Sabel et al. , 
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2011, Schmidt et al. , 2013). The most common AEs were skin sensations and irritation, 
headache, drowsiness, and sleep disturbances. No device-related SAEs were reported. 
No incidents occurred since the market introduction of a commercial device for ONS in 
2014, and it can be assumed that the likelihood of detrimental effects is probably 
extremely low. 
 
6.7. Transcutaneous spinal direct current stimulation (tsDCS) 
During transcutaneous spinal DCS (tsDCS) (Cogiamanian et al. , 2008) the current 
is delivered through a skin electrode positioned over the spinal cord with the return 
electrode placed over various regions according to different protocols (mainly the 
shoulder, the anterior aspect of the trunk, or somewhere along the spine). It has been 
used in patients with spinal cord injury (Hubli et al. , 2013) and with restless leg 
syndrome (Heide et al. , 2014). The technique appears to influence ascending and 
descending spinal pathways and to modify the excitability of various spinal reflexes in 
humans and animals (for review see (Priori et al. , 2014)). In general, anodal tsDCS tends 
to suppress conduction along spinal pathways and to facilitate reflexes, while cathodal 
spinal tDCS tends to enhance responses mediated by spinal ascending pathways and 
inhibit reflexes (Priori et al., 2014). In addition, tsDCS may induce indirect functional 
changes in the brain (Bocci et al. , 2015a, Bocci et al. , 2015b, Bocci et al. , 2015c).  
None of these studies reported SAEs, and serum NSE levels were unchanged 
(Cogiamanian et al., 2008). Spinal DC stimulation did not damage the spinal cord in rats 
(Ahmed, 2011) with the estimated current density being well below the threshold for 
neural tissue damage (McCreery et al. , 1990). Data concerning tsDCS have been so far 
been only collected in adults, usually after a single session involving the thoracic spine. 
Modeling data (Parazzini et al. , 2014) suggest that the current density may be slightly 
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higher in smaller subjects and children. Harmful effects due to the higher current 
density through spinal foramina or intervertebral space are not anticipated, but cannot 
be excluded. 
Recommendations: tsDCS in young subjects or children, especially based on 
multiple stimulation sessions with intensities and/or durations greater than those 
conventionally used should be carefully evaluated within controlled studies. The specific 
case of pregnancy is addressed in the next chapter. In other conditions, there is 
theoretically no higher risk to stimulate the spinal cord than the brain. 
 
6.8. TES and pregnancy 
EFs attenuate rapidly with distance, so it is unlikely that the fetus would be 
directly affected by TES. A calculation of current intensities arriving at different parts of 
the body (e.g., heart, uterus) during transcranial stimulation has not been performed yet. 
There are only two published case reports of pregnant women who underwent tDCS 
treatment for depression and hallucinations related to schizophrenia (Shenoy et al. , 
2015, Vigod et al. , 2014). The first case reported was a 25-year-old woman with 
schizophrenia (DSM-IV) and drug non-responsive auditory verbal hallucinations 
(Shenoy et al., 2015). The stimulation intensity was set at 2 mA for 20 min with sessions 
twice a day (separated by at least 3 h) for 5 consecutive days with an anode at F3 and 
FP1 and the cathode at T3 and P3 positions. The patient responded well with nearly full 
remission of hallucinations until follow-up at one month after tDCS. Repeated 
sonography at this time showed a healthy fetus (22 weeks) without any abnormalities 
and the pregnancy was uneventful as ascertained again by an obstetrician.  
The second case was a 23-year-old woman with depression from her 6th week of 
pregnancy who was successfully treated using a bifrontal electrode placement with 
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anode corresponding to the F3 area and the cathode corresponding to the F4 area on the 
scalp (Sreeraj et al. , 2016). A direct current of 2 mA was delivered for 30 minutes daily 
for 10 days. Here a minor AR was reported, in 3 out of 10 tDCS sessions during the fade-
in phase the patient experienced transient, mild burning sensations at the site of 
application and fleeting experience of phosphenes. There was no detailed information 
reported on the course of pregnancy including the fetus in terms of malformations and 
growth. 
Recommendation: In controlled studies the entrance questionnaire should ask 
about pregnancy, and pregnant subjects should be stimulated only if the benefit is 
higher than the risk. Due to the higher field intensities and the location of stimulation, 
direct stimulation over the lumbar spine should likely be avoided in pregnant women. 
Furthermore, although risks for the embryo or fetus during TES are logically negligible, 
the risk is actually unknown, and it should be recognized that any research on medical 
products in pregnant women is regulated by law.  
 
6.9. TES-associated AEs in pediatric populations 
tDCS may play an important future role in the treatment of developmental 
disorders (Ciechanski and Kirton, 2016, Palm et al. , 2016b). If the intention is to 
approximate brain current densities produced in adults, then the tDCS dose in children 
needs attenuation in order to compensate for the thinner skull and lower resistance 
(Gillick et al., 2014, Kessler et al., 2013, Moliadze et al. , 2015b), though 2 mA has been 
tested without incident in children (Ciechanski and Kirton, 2016, Mattai et al. , 2011). 
The main findings of tDCS applications in this population are summarized in Tables 5 
and 6.  
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In 48 studies on transcranial magnetic and electric stimulation, involving more 
than 513 children and adolescents (Krishnan et al. , 2015), AEs were generally mild and 
transient, and very similar to those in adults. In patients with congenital hemiparesis (7–
18 years; n=13) a single session of tDCS (0.7 mA for 10 min) was well tolerated with no 
changes in vital signs or worsening of motor function (Gillick et al. , 2015b). 
Children suffering from various neuropsychiatric disorders (n=14; 5-12 yrs) 
were given multiple-session tDCS (2mA; 30 min daily for ten days) (Andrade et al. , 
2014). The main AEs reported were mood changes, skin sensations (itching, tingling, 
burning), headache and sleepiness, but it is uncertain whether or not these complaints 
might not be attributed to the neuropsychiatric disorders themselves rather than to the 
stimulation. 
Twelve patients (mean age = 15.4, range 10-17 yrs) with childhood-onset 
schizophrenia were treated with repeated 2 mA tDCS (2 mA, 20 min, ten sessions) 
(Mattai et al., 2011). There was no clinically significant improvement of mood, arousal, 
or verbal output. A randomized, controlled, crossover study of the AEs of tDCS in healthy 
children and adolescents (mean age 13.9, range 11-16 yrs) showed that tDCS with 1 mA 
intensity over 10 minutes is well tolerated in children and adolescents. No pathological 
oscillations, and in particular, no markers of epileptiform activity, after 1mA tDCS were 
detected in any of the EEG analyses (Moliadze et al. , 2015a). Long-term EEG monitoring 
was not performed (Bogdanov et al. , 1994, Moliadze et al., 2015a).  
No AEs were seen in young patients, even after tDCS was applied with a higher 
than usual current density (0.497 mA/cm2) and/or repeated over several days (Breitling 
et al. , 2016, Mattai et al., 2011, Munz et al. , 2015, Schneider and Hopp, 2011, Soff et al. , 
2016). tDCS was applied to some children during sleep without awakening them, and 
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none reported AEs the following morning (Munz et al., 2015, Prehn-Kristensen et al. , 
2014a).  
All studies in both adults and children showed that tDCS does not elicit epileptic 
seizures or provoke epileptic EEG activity in patients with known epilepsy (Varga et al. , 
2011). A four-year-old boy with a history of idiopathic infantile spasms suffered a 
probably unrelated partial onset seizure four hours after his third anodal tDCS session 
(anodal tDCS of right M1, 1.2 mA, 20 min, 25 cm2 electrodes) (Ekici, 2015). The child had 
been free from seizures under medication with valproic acid and topiramate for the 
previous two years. Topiramate had been tapered off two weeks prior to tDCS and he 
was receiving escitalopram (2.5 mg) prior to tDCS to facilitate excitatory effects, so the 
situation was complicated. No firm conclusions can be drawn regarding a potential 
epileptogenic interaction of serotonergic medication and anodal tDCS (Ekici, 2015).  
Major reported AEs and related stimulation protocols in children are summarized 
in Table 6. 
Recommendations: The type and magnitude of reported AEs does not differ 
between children/adolescents and adults, available evidence delivers no established 
risks specific to tDCS, and thus recommendations match those for adult populations. 
There are no published data concerning long-term after-effects of TES in 
children/adolescents. 
 
6.10. TES-associated AEs in aging populations 
The majority of studies of tDCS in healthy, older adults do not differ from those in 
younger adults methodologically (standard electrode montages with prefrontal, 
precentral, temporal, or parietal locations of the target electrode (size 25 to 35 cm²) 
with a supraorbital or vertex return electrode (same size or up to 100 cm²)). A weak (1 
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to 2 mA) anodal current was usually applied for 15 to 30 min. About one-third of the 
studies published until 2016 in aging populations reported no occurrence of tDCS-
related AEs without giving details (Table 7). The most commonly reported AEs were 
typical tingling and itching that usually occurred when stimulation began but were also 
reported under sham conditions, where stimulation was applied only for a short 
duration at the beginning of the session (Boggio et al. , 2010, Fertonani et al. , 2014, 
Gandiga et al. , 2006, Harty et al. , 2014, Hoff et al. , 2015, Holland et al. , 2011, 
Learmonth et al. , 2015, Manenti et al. , 2013, Parikh and Cole, 2014, Sandrini et al. , 
2014, Sandrini et al. , 2016). 
Anodal tDCS (2 mA, 15 min) applied over the cerebellum (return electrode over 
the buccinator muscle) was not significantly more painful than sham stimulation 
(Hardwick and Celnik, 2014)(see Table 7). Similar results were seen in a study of 
anodal tDCS (1 mA, 20 min) over the M1 with a supraorbital return electrode (20 min, 1 
mA) with regard to attention, discomfort and fatigue (Hoff et al., 2015).  
Burning sensations and slight “pinching” were reported by 72% and 32%, 
respectively, following tDCS of the left DLPFC (2 mA, 10 min, shoulder reference 
electrode) but there was no difference between active and sham stimulation (Fertonani 
et al., 2014). Pruritus was reported after cathodal and anodal stimulation with the same 
active electrode placement (1 mA, 37.5 min, vertex return electrode) and was more 
intense following active stimulation (Harty et al., 2014). There was no correlation 
between pruritus and task performance. Similarly, Learmonth et al. (2015) observed 
slightly more burning sensations during active stimulation sessions in older adults that 
received parietal anodal tDCS with a supraorbital reference for 15 min with 1 mA 
(Learmonth et al., 2015).  
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The only study of AEs during tACS in healthy older adults (Antonenko et al. , 
2016) used 5x7 cm² or 10x10 cm² electrodes with a temporo-parietal/supraorbital 
montage. tACS was administered at 6 Hz for 20 min. The sensations experienced by the 
twelve older participants were tingling (n=3), itching (n=1), fatigue (n=2) and loss of 
concentration (n=2) during either active or sham tACS. Participants were unable to 
reliably identify the active stimulation session. 
Conclusions and recommendations: The quality of reported AEs does not differ 
between young and old subjects; they are milder in older adults and tend to disappear 
during stimulation, and do not significantly affect task performance (Fertonani et al., 
2014, Hardwick and Celnik, 2014, Learmonth et al., 2015) (see Table 7). The incidence 
does not differ significantly between active and sham stimulation, indicating the 
effectiveness of the standard fade-in fade-out sham stimulation at least in naïve subjects 
(Hummel et al. , 2010, Lindenberg et al. , 2013, Manor et al. , 2016, Parikh and Cole, 
2014, Sandrini et al., 2014, Sandrini et al., 2016, Zimerman et al. , 2013). Not 
surprisingly, the identification of the actually applied stimulation paradigm is more 
accurate after repeated sessions (Nilsson et al. , 2015, Wallace et al. , 2016). Validated 
standardized questionnaires are required for assessing AEs in older adults. From 
pharmacological interventions, it is well-known that older adults are more susceptible 
to negative effects on cognition, mood, or increased dizziness, than younger subjects 
(Thiem, 2012) and these issues should be better checked in future studies.  
 
6.11. Special considerations for intracranial implants 
Simulations suggest TES in the present of DBS will not result in significant 
concentration of current in the brain (Bikson et al., 2016a). In 10 subjects with 
intracranial EEG electrodes, 0.5 to 2 mA tACS with frequencies up to 100 Hz was applied 
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with no adverse events, producing 0.4 V/m electric field per mA (Huang et al. , 2017). In 
a separate study, in two epilepsy patients with implanted electrode grids, 1 Hz 
alternating current of 1 mA was applied to the bitemporal area for two minutes (Opitz et 
al., 2016). Patient 1 had bilateral stereotactic EEG electrodes and patient 2 had left 
subdural grid, strip and depth electrodes. No AEs were reported. The highest 
magnitudes of EFs were found in superficial sites near the stimulating electrodes, with 
maximum EF strength of ~0.36 mV/mm for patient 1 and ~0.16 mV/mm for patient 2. 
These results from intra-cranial recording are in the range predicted by modeling 
studies for tDCS (Datta et al., 2009a, Miranda et al., 2013). The study also tested tACS in 
two monkeys with stereotactic EEG electrodes, and here, similarly, no adverse 
physiological reactions were identified. 
ECT has been performed in 24 patients with implants (eight with cerebral 
clipping systems, two with cerebral coils, four with DBS, seven with other types of 
metallic implants, and three with foreign bodies), with no AEs related to the presence of 
these objects (Gahr et al. , 2014). As of July 2016, at least ten patients with DBS for 
treatment of PD, cervical dystonia, essential tremor, depression and obsessive 
compulsive disorder have been treated with ECT without AEs (Rosenthal et al. , 2016). 
In most cases, the DBS system was turned off during ECT to prevent inadvertent DBS 
activation, but ECT has also been performed with the device on (Vila-Rodriguez et al. , 
2014). In some cases, the ECT protocols were modified to maximize the distance 
between the ECT electrodes and the DBS electrodes or the subcutaneous leads. 
Several ex vivo studies showed that TMS over DBS leads did not induce sufficient 
current to cause tissue damage or damage to the pulse generator (Kuhn and Huebl, 
2011, Kumar et al. , 1999), although stimulation over lead loops could potentially 
produce current large enough to be dangerous (Shimojima et al. , 2010) (Deng et al. , 
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2010). At least 20 TMS studies in patients with DBS have been published since 2001 
(Chen et al. , 2001) and no AEs have been reported. TMS-induced current in the DBS 
stimulator leads has been claimed to be sufficient to activate the internal capsule 
(Hidding et al. , 2006, Kuhn et al. , 2002) as demonstrated by shorter latencies MEPs. 
However, this was not found in other studies (Kuriakose et al. , 2010). These differences 
may be related to the location of the TMS coil relative to the DBS leads and the presence 
of lead loops. An ex vivo study and testing in a patient found no safety concerns with 
rTMS over subdural cortical electrodes (Phielipp et al. , 2017). The current TMS safety 
recommendation states that TMS can be safely applied to patients with implanted 
stimulators of the central and peripheral nervous system (Rossi et al., 2009). Therefore, 
tDCS with its much lower intensities is unlikely to be associated with significant heating, 
current induction or movement of implanted devices. Induction of chemical reactions 
with galvanic currents in implanted electrodes is an unsolved issue when tDCS is applied 
close to subdural or epidural electrodes, or to the leads of DBS electrodes. This effect 
may be amplified by the lower resistance of the burr hole if the transcranial electrode is 
closer than approximately 2 cm (Datta et al., 2010). Another concern could be the still 
unknown combined biological effects of tDCS with intracranial stimulation since both 
tDCS and DBS (Kim et al. , 2015, Udupa et al. , 2016) can induce cortical plasticity 
alterations. 
Recommendation: TES should be performed on humans carrying any implants 
in the brain or in the skull only in well-supervised and controlled studies. 
 
6.12. Safety concerns: Illness-therapy-stimulation interactions  
TDCS can be combined with basically any other therapeutic intervention. Pairing 
tDCS with motor or cognitive training or behavioral interventions (Bajbouj and Padberg, 
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2014, Wessel et al. , 2015) or the application of selective serotonin reuptake inhibitors 
(SSRI) combined with tDCS in depression (Brunoni et al. , 2013b) are examples of 
meaningful combinations. Combinations of tDCS with motor or cognitive training or 
behavioral interventions appear to be safe (in stroke and in neurorehabilitation). 
However, some behavioral interventions might increase the risk of AEs, e.g. excitatory 
tDCS after sleep deprivation may amplify cortical excitability changes. No such 
interaction has been reported so far.  
In the following sections we concentrate on reported AEs in the most frequently 
TES-treated patient groups: major depressive disorder (MDD), stroke and chronic pain. 
From other patient populations we have less information, and even in these major 
groups there is a considerable heterogeneity in AE reporting. 
 
6.13. Published AEs in depression  
The burden associated with TES in MDD trials was basically the same as in all 
other trials with tDCS, i.e., cutaneous symptoms and sensations occurring with the same 
frequency (Aparicio et al. , 2016). Four RCTs (Bennabi et al. , 2014, Brunoni et al. , 2013c, 
Loo et al. , 2012, Loo et al. , 2010) described treatment-emergent mania/hypomania in a 
total of ten cases: nine in the active and one in the sham groups (Table 8). Loo et al. (Loo 
et al., 2010) described a tDCS-induced hypomanic episode (anode over the left DLPFC, 
cathode over the right supraorbital region, 20 min/day, 1mA) after eight sessions of 
active tDCS in a 57-year old woman who was not using any medications (Arul-Anandam 
et al. , 2010). In their second trial using active tDCS (same montage as previously 
described, 20 min/day, 2mA), Loo et al. (Loo et al., 2012) induced a hypomanic episode 
after six sessions of tDCS in a type I bipolar, 78-year-old woman who was on lithium, 
quetiapine and fluoxetine. Brunoni et al. (Brunoni et al., 2013c) later reported six cases 
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of tDCS-induced hypomania/mania. All patients (two male, four female, aged between 
25 to 62 year-old) were antidepressant-free before trial onset. In one case, a hypomanic 
episode was triggered by tDCS-only. In the other five cases, the combination of tDCS 
with sertraline 50mg/day induced hypomanic (three cases) or manic episodes (two 
cases, one of them with psychotic symptoms, as described in (Brunoni et al. , 2011b)). 
The treatment protocol was anode over the left, cathode over the right DLPFC, 
30min/day, 2mA stimulation session. Finally, Bennabi et al. (Bennabi et al., 2014) 
reported one case of tDCS-induced mania in the active group, using a treatment protocol 
of anode over the left DLPFC, cathode over the right supraorbital region, 30min/day and 
2mA current intensity.  
Besides the abovementioned RCTs, there are two additional case reports of tDCS-
induced hypomania. Baccaro et al. (Baccaro et al. , 2010) reported a tDCS-induced 
hypomanic episode in a 58-year-old man with a depressive episode secondary to gastric 
cancer. The hypomanic episode was triggered after five sessions of bifrontal tDCS (2mA 
intensity, 30min/day) and resolved only after discontinuing treatment and initiating 
lamotrigine treatment. Galvez et al. (Galvez et al. , 2011) described the case of a 33-year-
old female with bipolar II disorder on mood stabilizer medication who underwent 
bifrontal tDCS without incident, however later became hypomanic when receiving a 
second course of frontoextracephalic tDCS. In this context, it is also worth noting a case 
series of five bipolar depressed patients treated with bifrontal tDCS (2mA intensity, 
30min/day, 10 sessions) (Pereira Junior Bde et al. , 2015). A patient who was at baseline 
in a mixed depressive state exhibited an initial improvement, but with recrudescence of 
depressive and manic symptoms during the trial, showing overall no improvement with 
tDCS. Another patient presented an increase of the Young Rating Manic Scale (YMRS) 
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from 2 to 11 during the trial, although no clinical diagnosis of hypomania/mania was 
performed.  
In summary, 11 cases of tDCS-induced hypomania/mania episodes have been 
described, of which only two occurred in patients with a bipolar disorder. Five patients 
out of these 11 cases started receiving tDCS and sertraline simultaneously. In a recent 
meta-analysis on the topic, Brunoni et al. (Brunoni et al. , 2016) found that the 
treatment-emergent hypomania/mania rates were not statistically different between 
active and sham stimulation, although they were higher in active (3.5%) vs sham (0.5%) 
stimulation. 
Treatment-emergent suicidal ideation or behavior is a risk in the treatment of 
any depressed patient. One patient committed suicide during a clinical tDCS trial, but 
this was most likely unrelated to tDCS intervention (Loo et al., 2010). A PubMed search 
failed to find other psychiatric AEs induced by tDCS (hallucinations, psychosis, anxiety, 
etc).  
Recommendation: patients should be carefully assessed for a history of bipolar 
disorder or of switching into mania with past antidepressant treatments, as these 
factors may indicate a higher risk of manic switch with tDCS. In these patients, 
concurrent treatment with mood stabilizer medications during the tDCS treatment 
course should be considered. In this context, the use of lithium and antipsychotic drugs 
should be preferred over anticonvulsant medications, which can decrease or abolish 
anodal tDCS effects (Brunoni et al. , 2013a).  
 
6.14. Review of published AEs in chronic pain 
In the period 2005 to 2016, 43 of the 54 tDCS studies performed in pain patients 
reported the incidence of AEs (Lefaucheur, 2016). Of these 43 studies, 34 reported AEs 
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without having used a questionnaire or without details of the questions or the results 
obtained with the questionnaire. Three-quarters of these studies reported AEs occurring 
during or after their tDCS protocols, mainly tingling at the stimulation site (44% of 
active procedures and 47% of sham procedures) and sleepiness or fatigue (31% after 
active procedures and 21% after sham procedures). In many case, the occurrence of AEs 
in chronic pain patients was significantly higher during or after active tDCS condition 
than during or after sham tDCS. With regard to skin redness at the electrode site, it was 
observed more frequently for active tDCS than for sham tDCS (20% vs. 11%).  
Four dropouts in pain studies were the result of AEs such as skin reaction at 
stimulation site (n=3) or increased pain (n=1). The latter event could be interpreted as a 
lack of tDCS efficacy in treating the pain syndrome rather than as an AE produced by the 
stimulation. These pain therapy studies also reported three cases of skin burn due to the 
electrodes, which healed within a few days, leaving a small scar in one patient (Oliveira 
et al. , 2015). 
In nine studies using a structured questionnaire on the occurrence of AEs in 
migraine (Antal et al. , 2011a, Dasilva et al. , 2012, Poreisz et al., 2007, Wickmann et al. , 
2015), fibromyalgia (Fagerlund et al. , 2015, Mendonca et al. , 2016), 
temporomandibular disorders (Donnell et al. , 2015), irritable bowel syndrome (Volz et 
al. , 2016), or a mixture of various neuropathic and non-neuropathic pain syndromes 
(Antal et al. , 2010) the frequency of reported AEs was 20 to 50% higher than in studies 
with spontaneous reporting. Here also the most frequent AEs were tingling at the 
stimulation site (51% of either active or sham), and sleepiness or fatigue (39% after 
active and 45% after sham). The incidence of skin redness at the electrode site was high 
in both the active tDCS (50%) and sham tDCS (46%). However, it should be noticed that 
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sham stimulation usually includes a very brief stimulation period at the beginning of 
each session.  
Conclusion: patients with pain syndromes do not have a lower tolerance for TES 
than other patients. Furthermore, there is currently no solid evidence to suggest that the 
AEs in these patients are significantly higher in the active condition than in the placebo 
condition.  
 
6.15. Published AEs in post-stroke treatment 
In the stroke domain, 58 of the 86 tDCS studies published in the period 2005 to 
2016 containing the data of 788 patients reported the incidence of mild and transient 
AEs. Fourteen events led to discontinuation of the treatment (Gillick et al. , 2015a, Jo et 
al. , 2009, Kim et al. , 2010, Làdavas et al. , 2015, Mortensen et al. , 2016, Polanowska et 
al. , 2013, Rosso et al. , 2014, Shigematsu et al. , 2013, Smit et al. , 2015, Sparing et al. , 
2009, Straudi et al. , 2016a, Sunwoo et al. , 2013, Triccas et al. , 2015b, Wang et al. , 2014, 
You et al. , 2011).  
The most common AEs were headache in 16 of the 788 patients (Kim et al., 2010, 
Mortensen et al., 2016, Sunwoo et al., 2013), burning and aching (12/788), skin 
irritation (14/788), tingling and itching under or around the electrode (5/788), and 
nonspecific discomfort (4/778) (Gillick et al., 2015a, You et al., 2011). One patient 
suffered a possibly allergic skin reaction (Triccas et al., 2015b), probably to the applied 
crème, while one required a lotion for skin dryness following the stimulation session 
(Smit et al., 2015). One patient experienced a “sudden psychological disturbance” during 
bi-hemispheric stimulation of the parietal cortex (2mA, 20 mins, 1 session) similar to 
that seen with application of TMS to the same location (Schutter et al. , 2009).  
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No patient reported fatigue (Ang et al. , 2012, Bae et al. , 2012, Giovannella et al. , 
2016, Kongthong et al. , 2011, Ridder and Vanneste, 2012, Schestatsky et al. , 2013, Smit 
et al., 2015). Since tDCS may affect sympathetic tone (Rossi et al. , 2016) and 
cardiovascular stability is crucial, particularly in the acute post-stroke period (Al-Qudah 
et al. , 2015, Beeli et al. , 2008, Makovac et al. , 2016, Santarnecchi et al. , 2014, 
Vandermeeren et al. , 2010, Vernieri et al. , 2010) there might be a theoretical risk of 
arrhythmias or hypertensive crisis in stroke patients. However, prolonged monitoring 
during and after tDCS in healthy subjects failed to show an influence on vital functions. A 
short lasting linear increase of systolic/diastolic blood pressure in healthy subjects 
unrelated to the polarity of stimulation and to tDCS-induced changes on corticospinal 
excitability (Santarnecchi et al. 2014) awaits confirmation.  
Another issue that has been raised is whether tDCS in stroke patients would have a 
higher risk of inducing seizures. Indeed, about one third of tDCS clinical trials in stroke 
exclude patients with history of seizures and/or epilepsy (Russo et al. , 2017). However 
there have been no cases of confirmed seizures induced by tDCS regardless of the risk of 
seizures. A recent study provides initial evidence for the safety of tDCS intensities up to 
4 mA in stroke treatment (Chhatbar et al. , 2017). 
 
6.16. Pharmacological interventions combined with tDCS: Interactions 
between tDCS and concomitant drug treatments 
Interactions between TES and concomitant treatment with centrally acting drugs 
may potentially augment the efficacy of TES. However, this may also increase AEs (or 
conversely might reduce them). First, local drug application may ameliorate AEs 
associated with tDCS. Topical ketoprofen reduced erythema under the electrodes 
(Guarienti et al., 2015), and a topical local anesthetic emulsion (e.g., 2.5% lidocaine or 
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prilocaine) reduced discomfort during stimulation (McFadden et al., 2011). EMLA® 
cream is also very effective in anesthetizing normal skin. This could help to improve 
blinding in controlled studies. Blunting cutaneous sensation does not correlate with the 
degree of skin injury (Palm et al., 2014), and with correctly performed stimulation 
technique, therefore topical anesthesia should not increase the risk of injury (Woods et 
al., 2016b). 
Second, tDCS has been applied together with pharmacological interventions in 
healthy humans as well as in patient populations to explore and potentially boost the 
effects of stimulation (for overview see (Brunoni et al., 2013a, Nitsche, 2012)). Also, the 
standard pharmacotherapy for the disorder for which tDCS is employed as an adjuvant 
measure should usually be continued. Drugs such as benzodiazepines may interfere with 
a beneficial outcome in depressive disorders (Brunoni et al., 2013a). The reported 
effects were either AEs typical of tDCS or of the medication, e.g., vertigo, tiredness, 
vomiting, (dopaminergics, NMDA receptor antagonists or benzodiazepines). No SAEs 
have been reported with combinations, e.g., tDCS and clozapine (Arumugham et al. , 
2016). Thus, currently there is no evidence that the combination of pharmacotherapy 
with tES results in enhanced risks exceeding AEs, which can attributed to the respective 
single interventions. 
 
6.17. Interactions between TES and concomitant treatment in 
neurorehabilitation  
A PubMed search of the literature from 2000 to 2016 was conducted for 
neurorehabilitation studies using “tDCS” in combination with “neurorehabilitation” and 
“rehabilitation” as the search terms followed by searches on symptoms or disorders 
such as “aphasia” or “multiple sclerosis” treated with tDCS. Pain treatment studies were 
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included in cases where the pain had a central nervous system etiology (e.g., spinal cord 
injury). A total of 232 studies met the criteria, of which 115 studies (49.6%) explicitly 
reported safety outcomes in sufficient detail to allow for quantification of AEs across 
studies. The remaining 117 were unsuitable for the analysis of safety issues.   
In the 115 suitable studies, the number of participants per study condition (real 
or sham tDCS) was tallied. Participants were counted once for each study condition (i.e., 
twice in crossover studies), giving a total of 2260 participants x conditions (hereafter 
referred to as “subjects”). A total of 506 tDCS-related AEs were reported for an overall 
incidence of 22.4%. The actual incidence of AEs is probably somewhat lower because 
some subjects may have reported multiple complaints. The most common reported AEs 
were mild sensory phenomena that only occurred during stimulation at or near the 
electrodes (tingling, itching, phosphenes) that occurred in 253 (11.2%) subjects (e.g., 
(Grecco et al. , 2014a, Triccas et al. , 2015a)). Transient events included skin irritation 
(75 subjects; 3.3% (Ferrucci et al. , 2014, Triccas et al., 2015a)), issues with sleep or 
energy level, including sleepiness, fatigue, and insomnia (74 subjects; 3.3%; e.g., 
(Lesniak et al. , 2014, Murray et al., 2015)), headache or nausea (56 subjects; 2.5%; 
(Khedr et al. , 2014, Kim et al. , 2014)), problems with concentrating (15 subjects; 0.7%; 
e.g., (Wrigley et al. , 2013)), and neck pain (4 subjects; 0.2%; e.g. (Straudi et al. , 2016b)). 
An additional ten subjects (0.4%) experienced AEs that were deemed by investigators to 
be ‘adverse’ but were not well described ((Fusco et al. , 2014)). A total of 19 subjects 
(0.84%) withdrew from their respective studies because they did not tolerate the AEs. 
Subjects who received real tDCS reported a higher overall incidence of AEs (342 of 1323; 
25.9%) than those with sham tDCS (164 of 397; 17.5%), which might be due to the fact 
that the conditions were not satisfactorily blinded in some studies. The rate of study 
withdrawal was higher among subjects who received real stimulation than those with 
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sham stimulation (16 vs. 3 subjects), although the drop-out rate was low for both 
conditions (1.2% and 0.3%, respectively). 
 
6.19 Conclusions of human trials and recommendations 
No SAEs were reported for either real or sham TES between 2000 and 2016 with the 
exception of an epileptic seizure in an epileptic child (Ekici, 2015) and suicide in a 
depressed patient in a clinical trial (Loo et al., 2010)– in both cases the causality to tDCS 
was not proven. When reviewing only conventional bipolar tDCS in human applications 
and clinical trials no reports of an SAE or irreversible injury attributable to tDCS were 
found in over 33,200 sessions and 1000 subjects with repeated sessions (Bikson et al., 
2016b).  
About 300 publications using low intensity TES between 2000 and 2016 reported 
mild AEs, mainly in the category of skin sensations; however, several studies were not 
placebo controlled and double blinded. At present there is no solid evidence to suggest 
that the AEs in patients or in vulnerable populations are significantly higher and 
different in magnitude in comparison to healthy subjects. However, in several individual 
clinical trials a higher prevalence is reported. For example, in MDD some randomized 
clinical trials (RCTs) (Brunoni et al., 2013c, Loo et al., 2012, Loo et al., 2010) actively 
surveyed for AEs, and therefore the reported AE prevalence was much higher compared 
to other RCTs (Bennabi et al., 2014, Blumberger et al. , 2012, Palm et al. , 2012). In fact, 
in a recent systematic review of 64 tDCS trials (Aparicio et al., 2016), it was found that 
the quality of AE reporting was quite low – MDD trials only complied with 31.3% of the 
items described by CONSORT-harms (a “gold-standard” questionnaire for adequate AE 
reporting). Lack of adequate AE reporting is a concern because this usually leads to an 
underestimation of the true rate of AEs, which can, in turn, result in safety and blinding 
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issues. Therefore, better reporting of AE both in clinical and investigational applications 
of TES is warranted.  
 
7. Ethical, legal and regulatory issues 
7.1. Ethics 
Previous studies using transcranial stimulation suggest that ethical awareness 
was and is always linked to the social definitions and moral issues, both in health and 
disease (Harris and Almerigi, 2009, Moan and Heath, 1972). Nowadays a very careful 
assessment of the Institutional Review Boards (IRB) and Ethical Committees of a given 
institute is required before a study is initiated. Nevertheless, the main responsibility 
with regard to the appropriate conduct and maintenance of a rigorous ethical 
framework remains the responsibility of the investigators. Similar to other 
interventions, in the TES area three basic ethical and legal requirements pertain to all 
research studies and clinical use: 
(1) Informed consent; (2) Risk-benefit ratio; (3) Equal distribution of burdens and 
benefits of research.  
Similar to magnetic stimulation studies (Rossi et al., 2009), TES studies could be 
divided into categories dependent on the requirements for protection of the participants 
and what benefits they might expect. However, we introduce a new category (high 
benefit, low risk, see 4): 
(1) Direct benefit, high risk: studies with diagnostic or therapeutic primary objective, 
including new therapeutic indications or protocols with potential direct clinical 
benefit for the participant. The acceptable risk for participants could possibly be high 
for such procedures that have not been tested for safety. Healthy subjects usually do 
not participate in these studies. 
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(2) Indirect benefit, moderate risk: studies with little or no expectation of a clinical 
benefit. The study is anticipated to provide valuable data for the development of 
treatments, for safety assessment, or for improving the understanding of the 
pathophysiology of neurological or psychiatric diseases. Healthy subjects do not 
usually participate in these studies but could be included as controls. However, if the 
risk of AEs is high, healthy subjects should not be recruited. 
(3) Indirect benefit, low risk: studies expected to yield important data on brain 
physiology, general pathology or on safety, but without any immediate relevance for 
clinical problems. Healthy subjects and clinical population can participate. 
(4) High benefit, low risk: studies expected to yield important data on cognition and 
brain physiology in healthy subjects and patient populations, with an immediate 
relevance for cognitive or motor improvement. Studies targeting neuroenhancement 
would fall into this category.  
Independently from the type of the study (research or clinical), stimulation 
parameters and protocols must always be chosen with clear goals and safety 
considerations in mind,  and be accepted by the Ethical Committee before initiation of a 
study. Alterations in research protocols should always be documented. When an 
unanticipated divergence from the approved protocol happens (e.g., higher intensity of 
stimulation was applied accidentally) it must be reported to the IRB/ Ethical Committee 
(timing depends on the legal regulations, usually after 7 days of their discovery).  
There are application specific concerns in the TES-ethics. One of the most discussed 
concerns the difference between treatment and neuroenhancement (see section 6.3.1). 
Some has suggested a theoretical, socially important problem is that the use of TES for 
cognitive and athletic enhancement of healthy subjects could increase natural 
differences between people, or even create new differences, leaving some individuals in 
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a disadvantaged condition (Lavazza, 2017). In fact, if TES methods were to be 
widespread in competitive contexts (e.g., exams, sport, job interviews), those who do 
not benefit from stimulation (or cannot afford to be stimulated for financial reasons) 
would be more disadvantaged compared to those able to enhance their skills thanks to 
neuromodulation. 
Other issues are associated with unlimited self-administration and related long-term 
consequences of stimulation. At present, there is little to no evidence of stimulation 
consequences for extended long-term use. The possible TES interactions with behavior, 
such as impulsivity, moral decisions, risk taking behavior (e.g., (Darby and Pascual-
Leone, 2017, Fecteau et al. , 2012)) are also frequently discussed points.  
Recommendations: Before entering a patient in a TES study, investigators should 
screen exclusion criteria by a standard questionnaire; consensus has been reached for 
the questionnaire in Table 9. (http://www.neurologie.uni-
goettingen.de/downloads.html.) Additional questions and information can be inserted 
according to particular experimental demands. An affirmative answer to one or more of 
the questions does not indicate an absolute contraindication to TES, but the risk-benefit 
ratio should be carefully checked and balanced by the principal investigator (PI) or by 
the responsible researcher/physician. If participants feel indisposed during or after the 
stimulation, they should be seen by a medical doctor. Self- or proxy-administration of 
tDCS at locations remote from the clinicians or investigator benefits from careful 
consideration of risks and mitigating factors (Charvet et al. , 2015). 
 
7.2. Regulatory aspects of TES in the USA and EU  
Though the regulatory frameworks differ among countries, the common 
principles include emphasis on the safety of participating subjects and on professional 
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conduct. Here the regulatory approaches taken in USA and Europe are addressed; 
nevertheless similar regulations and principles prevail in other parts of the world.  
In the USA, the framework comprises a complex system of regulations and 
recommendations issued by the Good Practices in Clinical Research, Code of Federal 
Regulations (CFR), and / or the Food and Drug Administration (FDA). CFR is accessible 
to everyone; regulations pertaining to protection of human subjects appear in Titles 21 
and 45. The FDA (Neurostimulation Devices Branch in the Division of Neurological and 
Physical Medicine Devices at the Office of Device Evaluation) defines medical devices as 
products that are “intended for use in the diagnosis of disease or other conditions, or in 
the cure, mitigation, treatment, or prevention of disease in man, or intended to affect the 
structure or any function of the body of man and which does not achieve any of its 
primary intended purposes through chemical action.” Medical devices not cleared by the 
FDA in the US are required to follow the Investigational Device Exemptions (IDE) 
regulation (21 CFR Part 812). This regulation describes three types of devices studies: 
significant risk (SR), non-significant risk (NSR), and exempt studies. Under 21 CFR 
812.3(m), a SR device study is defined as a clinical investigation using a device that is 
intended as an implant, is represented to be for a use in supporting human life, is for a 
use of substantial importance in mitigating and treating disease or presents a potential 
for serious risk to the health, safety or welfare of a subject. A NSR device study is one 
that does not comply with the definition for an SR device study. Certain studies are 
exempt from the requirements of 21 CFR Part 812, for example: studies of an already 
cleared medical device in which the device is used or investigated in accordance with 
the indications in the cleared labeling. So far, clinical studies using tDCS devices in the 
US have been classified as SR. Sponsors of investigational SR device studies are required 
to get an approved IDE from the FDA before starting their study. In addition, in 
65 
 
accordance with the regulations at Part 812, the study may not start until both FDA and 
the Institutional Review Board (IRB) of clinical setting have given their approval.  
The European Union (EU) with its 28 member states, represented by “Competent 
Authorities” (similar to the FDA but for individual countries, and while they do not 
clear/approve products they ensure that the products are built to a certain standard and 
that any clinical utility is evidenced), pursues the regulation of neuromodulatory devices 
in different ways. In the EU, equipment intended for medical use is regulated by the 
Medical Devices Directive 93/42/EEC, which is implemented in each member state in 
the form of a national act or regulations governing medical devices. The Medical Devices 
Directive defines a medical devices as “… any instrument, apparatus, appliance, 
software, material or other article, whether used alone or in combination, including the 
software intended by its manufacturer to be used specifically for diagnostic and/or 
therapeutic purposes and necessary for its proper application, intended by the 
manufacturer to be used for human beings for the purpose of: diagnosis, prevention, 
monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment, 
alleviation of or compensation for an injury or handicap; investigation, replacement or 
modification of the anatomy or of a physiological process; control of conception …” 
(Medical Device Directive 93/42/EEC). However, if a manufacturer specifies an intended 
purpose of a device that is not covered by the above definition, e.g., for wellness, well-
being or even for neuroscience research (e.g., for the investigation of physiological 
processes) the device does not fall under this directive and is therefore not regulated by 
the Medical Devices Directive (third intent of Article 1(2)(a) of the Medical Devices 
Directive; European Court Reports 2012: ECLI:EU:C:2012:742). One can thus find the 
same types of devices in versions for the regulated medical market and for the general 
market, where other regulations such as consumer safety regulations apply. Another 
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important case, which also might not be covered by the MDD, is Compassionate Use, i.e., 
discretionary therapeutic use of a medical device for which it was not explicitly 
intended. The regulatory approach to assess risks and benefits for non-therapeutic 
devices, including enhancement devices, diverges from the approach used for medical 
devices. Neither the FDA nor the EC regulate the off-label use of stimulators. 
The EU MDD distinguishes two important cases for medical devices made 
available to the user: with and without CE marking. Devices without CE marking are 
either custom-made devices or devices intended for clinical application. All other 
devices require CE marking. Making a device available is called “placing it on the 
market,” regardless of whether the device is new or refurbished, for payment or free of 
charge. Devices intended for clinical evaluation are to be used to test the performance 
intended by the manufacturer and to determine undesirable AEs during use. Such 
evaluations are part of the risk assessment of a device and are carried out by a duly 
qualified practitioner or other authorized person based on the virtue of her/his 
professional qualifications. The equipment for TES falls in the category of active medical 
devices, which depend on a source of electrical energy or any source of power. All active 
therapeutic devices intended to administer or exchange energy are in Class IIa, thus TES 
devices are Class IIa (MDD, Annex IX, rule 9). Any Class IIa device requires CE marking 
including the number of the notified body.  
All medical devices must fulfill the Essential Requirements for safety and 
performance described in Annex I of the Medical Devices Directive, which state that a 
device used for its intended purpose shall not compromise the safety of any person 
(patients, professional users, and other persons such as visitors). These requirements 
apply to both design and manufacturing. All risks associated with the use of the device 
shall constitute acceptable risks. The latter requirement leads to the necessity of a risk 
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analysis, including risks due to the ergonomic features of the product, taking into 
account the user environment and knowledge (i.e., risk of user error). Consequently, 
manufacturers need to establish a risk management process, define acceptable levels of 
risk and demonstrate that the remaining risk is acceptable or mitigated against in the 
design process. Manufacturers should participate in clinical evaluations of stimulators. 
These can consist in a critical evaluation of the relevant scientific literature or in a 
critical evaluation of the results of all clinical investigations, or a combination of both. 
The critical evaluation of the relevant scientific literature includes all aspects of safety, 
performance, design characteristics and intended purpose of the TES device. For 
literature evaluations, the equivalence of the considered devices and the compliance 
with the relevant essential requirements must be demonstrated. 
The Essential Requirements of the Medical Devices Directive require that the 
device be state of the art and that the manufacturer adhere to world-wide, European and 
national standards, such as the IEC 60601 family of standards. The IEC 60601 family 
consists of a series of technical standards for safety, performance and effectiveness of 
medical electrical devices. Part 60601-1 includes the general requirements for basic 
safety and essential performance for all medical electrical devices. The collateral 
standards (60601-1-X; X stands for a specific number) include requirements for specific 
aspects of safety and performance such as electromagnetic compatibility, and the 
particular standards (60601-2-Y) provide requirements for specific products. While 
there is a particular standard for electroconvulsive therapy equipment (60601-2-14) 
and also a particular standard for nerve and muscle stimulators excluding the head 
(60601-2-10), there is not yet a standard for TES. Consequently, the definition of the 
state of the art, as required by the Medical Devices Directive, is given by the basic and 
collateral standards, and the state of the art described in the scientific literature. As the 
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latter is naturally quite dynamic and sometimes contradictory, a particular norm for TES 
would be helpful.  
It is the responsibility of the manufacturer or its responsible representative on 
the European market to affix CE marking for a freely moving product within Europe. 
There are four ways to obtain the CE marking for Class IIa products: implementing full 
quality assurance (Annex II of the Medical Devices Directive), or EC declaration of 
conformity set out in Annex VII in combination with either the procedure relating to the 
EC verification (Annex IV), the production quality assurance (Annex V), or the product 
quality assurance (Annex VI).  
An important step in fulfilling the Essential Requirements is a documented 
clinical evaluation (Annex X). The EC gives explicit guidelines for the evaluation of 
clinical data in the context of medical devices both for manufacturers and notified bodies 
(MEDDEV. 2.7.1, rev 4, since 28/06/2016) (http://ec.europa.eu/DocsRoom/documents 
/17522/attachments/1/translations/en/renditions/native). Post-market surveillance 
by the manufacturer is required for products already on the market and the gathered 
data must be used to update the clinical evaluation and its documentation. Such 
surveillance is supported by the European Databank on Medical Devices (Eudamed) 
(European Commission Decision 2010/227/EU of 19 April 2010 on the European 
Databank on Medical Devices) and by the responsible authorities of each EU member 
state and is freely accessible. In the near future, the Global Medical Device Nomenclature 
(GMDN), which was developed by the European Standards body CEN, will completely 
replace the separate codes of medical devices in the EU member states. The GMDN code 
for a continuous current TES system is 62056.  
The manufacturer must be able to trace each device on the market and to 
perform continuing post-market surveillance. The manufacturer must implement a 
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systematic procedure for reviewing experience gathered from devices in the market. It 
is mandatory that incidents leading to, or possibly leading to, death, or a serious 
deterioration in the health of a patient or user be reported to the responsible 
authorities. This is required independent of whether a malfunction or deterioration in 
the characteristics and/or performance of the device occurred, or the labeling or the 
instructions for use were inadequate. Medical practitioners are also required to report 
such incidents. Reporting is also required for systematic recalls of a device by the 
manufacturer.  
Recommendations: Practitioners should know the basic regulatory aspects of 
the type of stimulator they are using. Practitioners must report all incidents related to 
the malfunction of a stimulator to the responsible authorities. In June 2016, the 
European Parliament and the Council reached an agreement for better surveillance and 
traceability of medical devices. Consequently, new regulations are expected for 2017 
and will apply for three years following their publication. We warn against the use of 
devices and methods unless they have shown both efficacy and safety in appropriately 
designed clinical trials. 
 
7.3. Safety of freely available (direct-to-consumer) brain stimulation devices 
Devices used by non-professionals for self-stimulation, which are available “over-
the-counter” on the internet are not at the main focus of this report. Nevertheless, 
approximately a dozen companies, mostly American, are at present marketing and 
selling ready-to-use brain stimulation devices directly to consumers (Wexler, 2016). 
These direct-to-consumer tDCS companies range from small shoestring operations to 
larger Silicon Valley start-ups with significant venture capital funding. Furthermore, 
because TES can be performed with relatively simple devices, laypersons have begun to 
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build their own tDCS devices for use on themselves, with the main goal of self-
improvement. They are part of a movement, informally known as the “do-it-yourself 
(DIY) tDCS” online community (such as Reddit.com or diytdcs.com).  
 To date, only two studies of direct to consumer tES-users exist. Jwa (2015) 
conducted a survey of those who use brain stimulation at home, and Wexler (Wexler, 
2016) presented a preliminary sketch of the practices of home users, based on 
qualitative research. In the Jwa (2015) sample (n=121), respondents were mostly males 
(94%) in their 20s and 30s (71%) who resided in North America (74%). Wexler 
(Wexler, 2016) studied how users attempt to measure the effects of tDCS, finding that 
those who use tDCS for cognitive enhancement often attempt to measure the effect by 
assessing their performance in cognitive tests that are freely available online. In 
contrast, those who use tDCS for self-treatment, typically for mood disorders, often rely 
on a subjective sense of self-improvement as evidence of efficacy (Wexler, 2016). To 
some extent, home users adhere to the current levels employed in scientific studies, 
though they tend to experiment with the duration and frequency of stimulation.  
There is little reliable data on the safety or effectiveness of direct-to-consumer 
brain stimulation devices. The only study to-date conducted outside the commercial 
realm found that stimulation with the Foc.us v1 device caused subjects to perform worse 
on the accuracy component of a working memory task than subjects who received sham 
stimulation (Steenbergen et al. , 2016). Companies such as Thync® and Halo 
Neuroscience® have conducted in-house studies, both on safety and efficacy, and have 
posted some of their data online, though little has been published in academic journals. 
Further, evaluations have been over several weeks of use, while many in the DIY 
community apply stimulation over longer periods. 
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In the USA a fundamental legal issue is whether direct-to-consumer brain 
stimulation devices should be considered medical devices, and therefore be subject to 
relatively stringent regulations, or instead be considered consumer products and thus 
subject to more lenient regulations (in the EU this is no issue: if the manufacturer 
specifies an intended use other than medical, the Medical Device Directory does not 
apply). The crux of the problem lies in the legal definition of a medical device, which 
depends not on a product’s mechanism of action but rather on its “intended use,” which 
is determined from a product’s advertising and labeling. In the United States, for 
example, a product is considered a medical device if it is intended for use in the 
diagnosis or treatment of disease or other medical conditions, or if it is intended to affect 
the structure or function of the body.  
Since many direct-to-consumer brain stimulation device manufacturers do not 
make medical claims, instead marketing their products for “enhancement” or “wellness,” 
it is unclear whether these products meet the first part of the definition of a medical 
device in the USA. Whether consumer tDCS devices meet the second part of the 
definition is a more difficult issue discussed in detail elsewhere (Wexler, 2015). To date, 
the only instance of regulatory enforcement was by the California Department of Public 
Health, which in May 2013 took action against a company called tDCS Device Kit, Inc., for 
violating California’s Sherman Food, Drug, and Cosmetic Law. No other regulatory 
authorities, in the United States or elsewhere, have issued formal statements or taken 
any kind of regulatory action with regard to direct-to-consumer tDCS devices.  
Many of the ethical questions that arise from the consumer use of brain 
stimulation go hand-in-hand with the regulatory ones, particularly with regard to safety. 
Although a device or technique might informally be referred to as “safe” or “unsafe,” it 
may be better to consider safety as the outcome of a constellation of variables that 
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include users (i.e., who is using the device), devices (what kind of device   utilize), and 
stimulation parameters (how they are using the device). In addition, safety may refer to 
acute issues (such as headache that may occur during stimulation) or long-term ones 
(such as potentially deleterious effects on cognition). 
With regard to short-term safety issues, no SAEs have been reported by tDCS 
home users either, at least not on the Reddit forum. In one survey of home users, 
approximately half of the respondents reported experiencing mild AEs during 
stimulation (Jwa, 2015). The long-term effects of tDCS on cognition are more difficult to 
measure. At least one study has suggested that using tDCS to “enhance” certain functions 
may impair others immediately after the application (Iuculano and Cohen Kadosh, 
2013). Thus, one of the main points of contention with regard to consumer tDCS is 
whether a technique that may—or may not—have detrimental effects on cognition 
should be freely available to the public. Along these lines, researchers and ethicists have 
been particularly concerned about the use of tDCS on children, especially since few 
laboratory studies have examined the effects of brain stimulation in this vulnerable 
population. 
Summary and recommendation: More data is needed on the consumer 
neurotechnology market with regard to the prevalence of AEs related the home use of 
tDCS, and the effects of repeated stimulation to help illuminate the most prudent 
pathway forward through the ethical and legal complexities of consumer brain 
stimulation. Thus, the IFCN warns against the use of DIY devices and methods unless 
they have shown both efficacy and safety (https://goo.gl/uZsXAb), and a recent open 
letter from researchers to the DIY community outlined the risks of the home use of 
electrical brain stimulation (Wurzman et al. , 2016).  
 
73 
 
7.4. Where should/could TES be performed and by whom? 
No legal obligations exist to prevent application of TES outside a hospital 
environment. However, the manufacturer of the medical device determines the scope 
the medical device including labelling, indented use, user and environment. That means 
that the manufacturer might specify a particular device for hospital use only. In clinical 
studies a decision on the risk-benefit ratio has to be made by the investigator and 
approved by the ethical committee or IRB. There are no fundamental scientific 
objections against home use exist either, since successful scientific studies on that topic 
have been published (e.g., (Andre et al. , 2016, Wickmann et al., 2015)). 
The first consideration in dealing with the question of where TES should be 
performed is the establishment of a risk profile. If the risk is more than minimal, as e.g., 
in patient populations, then it is suggested that stimulation is performed in a hospital 
setting. Risk should be assessed not only for the nature of the technique, but also for the 
subjects being studied (e.g., whether the population is vulnerable or whether there 
might be an interaction with concurrent medication). If there is no more than minimal 
risk, stimulation could be performed in a research setting outside a hospital or at home. 
The research setting should be approved by the responsible IRB or Ethics Committee, 
and written, informed consent should be obtained. If there were approved medical 
indications for home use, a signed document confirming that the subject understands 
the instructions and intends to use the device as prescribed, would be needed.  
In a situation that is deemed to pose no more than minimal risk, in which 
stimulation is conducted at a research center or at home, the critical issue should be the 
proper use of the equipment, and this would require adequate training. Training of 
researchers is considered below, but training is just as important for subjects if tDCS is 
to be performed at home. Remote supervision, possibly using the internet, would be 
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important in order to help prevent protocol violations and assure maximal safety (see 
e.g., (Perez-Borrego et al. , 2014) for an example of successful tele-monitoring of long 
term home use of tDCS therapy in a patient). To assist subjects with home delivery of 
tDCS, equipment functions could be restricted and/or simplified to encompass only 
specific stimulation needs. Stimulators should internally record and document 
stimulation parameters of each stimulation session; this would permit complete 
monitoring of what was done and also identify non-compliance.     
 
7.4.1. Training 
Training has two facets: 1) the correct use of the device, and 2) safety issues, i.e., 
knowing how to prevent and monitor for AEs, and how to deal with them should they 
arise. While physicians should be involved in any procedure that poses more than 
minimal risk, there is no requirement that persons performing the stimulation should 
have a specific profession. Researchers should know about the principles of TES and the 
physiology of its desired and undesired effects. Researchers, technicians and even the 
subjects themselves, in the setting of home use, would need to know how to set up the 
equipment, how to place the electrodes correctly, and how to assure the prescribed dose 
of stimulation. After a period of instruction, individuals should be assessed to make sure 
that they are able to perform all the procedures correctly. At present, the teachers are 
persons with the most experience in the field; both self-declared and recognized by 
others usually on the basis of their publications. In the long run, teachers might need a 
kind of certification such as warranted country-specific in other areas of the public 
health service. 
Recommendations: Persons performing TES should also know how to prevent, 
assess, report, and deal with AEs, when they occur. Skin burns are an acute moderate 
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risk if electrodes are improperly employed, and operators and patients should be alert 
to any feeling of pain or heat under the electrodes. In certain circumstances, it would be 
appropriate to know how to deal with cognitive or emotional changes. Since so far no 
confirmed incidence of seizures has ever occurred in the context of TES, training in 
dealing with seizures is not necessary at present.  
 
8. How to assure safety in the future? 
AEs have been rare and minor in the course of thousands of hours of TES in 
controlled settings. CE certified medical stimulation devices are current-controlled; they 
limit the maximum current delivered per electrode (<2-4 mA), the maximum stimulation 
voltage with an auto-abort option if the pre-set current cannot be delivered beyond a 
defined voltage level and the maximum total current delivered through all electrodes at 
any moment. They force users to set the program duration, and check impedance before 
and during stimulation. The following additional measures could further increase safety: 
1. Verification (visual inspection) of the stimulation parameters should be done before 
each stimulation session, when it is possible (e.g., when the study is not double 
blinded). Additionally, because, like any device, a TES device can malfunction 
without visible signs, a regular performance verification check by operators or 
manufacturers is also warranted (e.g., in every second year depending on country 
specific regulations). 
2. A standard system for reporting the multidimensional parameter space used for an 
experiment. Clearly defined protocols with specification of electrode type, positions, 
current type (DC/AC) and intensity, duration, and session sequencing allow for 
better reproduction, interpretation and comparison of results among laboratories, 
and facilitate the development of new applications. A longer, comprehensive and 
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shorter, basic checklist can be found in Table 10. The lists can be downloaded from 
the website http://www.neurologie.uni-goettingen.de/downloads.html. 
3. Specifically querying for known AEs: The use of standardized questionnaires that 
query about the occurrence of specific AEs and offer numeric scales for rating the 
intensity (e.g., (Fertonani et al., 2015, Poreisz et al., 2007)). We propose the 
publication of completed questionnaires even if no AEs occurred. Consensus was 
with the questionnaire in Table 11, which contains detailed questions regarding a 
thorough list of known AEs. It can be modified according to specific experimental 
conditions. The documents can be downloaded from the website: 
http://www.neurologie.uni-goettingen.de/downloads.html. 
4. Analyzing potential differences in specific populations such as between age-groups. 
Validated questionnaires for assessing AEs or any type of stimulation-associated 
sensation in older adults are not widely acknowledged as part of the research 
routine, and, if applied, are not standardized. From the realm of pharmacological 
interventions, it is well-known that older adults are more susceptible to negative 
effects on cognition or mood, or increased dizziness, in response to almost any 
central-nervous system-active drugs (Thiem, 2012).  
5. Unknown AEs: AEs not yet encountered or reported may be detected by explicitly 
asking about “other AEs/sensations.” For a better understanding and sorting beyond 
these categories of causality and severity, one may adopt a classification that was 
initially employed to target drug AEs (Rawlins, 1981). In this classification, type A 
AEs correspond to an excess of the intended effects (e.g., too much sedation, too 
much blood pressure lowering). Type B AEs occur in an unexpected form, with 
individual administrations or doses of an intervention, usually in subjects with a 
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particular susceptibility, and type C AEs only occur in chronic application of a 
procedure or substance.  
6. Reporting each patient’s guess for type of stimulation (active/sham) and reporting 
the researcher’s assessment of the patient’s propensity to complain (cf. Fertonani et 
al., 2015, Wallace et al., 2016) is required in controlled blinded studies. 
 
9. Summary 
Given the growing interest in the non-invasive TES technologies, in this paper a 
range of researchers, clinicians, ethicists, regulators and developers of devices / new 
technologies summarized safety and ethical questions surrounding the use of TES for 
the treatment of nervous system disorders as well as for non-therapeutic uses, including 
cognitive and functional enhancement. TES so far appears to be a safe technique. Typical 
mild AEs are itching, burning sensations under the electrode or transient, mild 
headaches. Moderate AEs are mainly skin burns, which can be controlled by preventing 
electrodes from drying, and improving skin-electrode contact. SAEs have not been 
reported. As in drug studies, the incidence of MAEs increases with the use of 
questionnaires, in parallel with the increase of incidence of AEs under placebo 
stimulation.  
Modeling and imaging studies suggest that the effects of TES are not limited to the 
targeted brain area, and some behavioral and therapeutic effects are probably mediated 
by distant brain regions affected via trans-synaptic connections and non-neuronal 
effects. Better understanding of these connections and effects, e.g., by pre-stimulation EF 
modeling for targeting definition, would enable us to improve the therapeutic 
approaches. Individual subject-specific modeling may lead to more reproducible results 
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across individuals, increasing safety further by minimizing current flow in non-target 
regions.  
Similarly, a better understanding of why some people do not respond to 
neuromodulation is needed. The determination of dose – biological effect relationships, 
optimal duration and repetition rate of stimulation in clinical studies, and definition of 
appropriate washout periods for different stimulation protocols are required. 
Simultaneous registration of EEG or fMRI to study physiological effects in these studies 
should be informative. It seems clear that a single session of tDCS is safe if done 
properly, however, much less is known about repeated sessions in the long-term, which 
is how it will be used for treatment and enhancement. Home use of TES could enable a 
more individualized treatment and probably increase efficacy, but requires a better 
understanding of the effects of more frequent patterns of stimulation and raises 
concerns about clinical supervision and regulations. Tele-monitoring of home use should 
help to better appraise and control the impact of tDCS therapy in a familiar surrounding.  
The safety of the method has mostly been verified in adults with intact skulls, no 
implants, etc. Other groups are less well studied, and even less is known about the long-
term effects and safety for the use of tDCS in children or elderly populations. Future 
research should carefully specify and limit duration, intensity, and repetition of sessions 
in these populations. More detailed and sensitive examinations for potential safety 
issues are required. Minor to moderate alterations in features such as mood, cognitive 
functions or motoric functions cannot be assessed using questionnaires completed by 
the stimulation subjects themselves. Depending on the possible range of AEs, sensitive 
neurological, psychological tests should be performed in studies using a double blind 
design, especially when higher stimulation intensities and/or longer durations are used 
that can strongly interfere with brain functions.  
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Other forms of low intensity TES methods, such as tACS, tRNS, have been studied 
less extensively. However, in case of generally using accepted tACS protocols, potentially 
induced AEs do not include structural or functional damage. For example, no seizure 
induction has been reported to date for tACS.  
Cognitive enhancement is perhaps the most widely publicized, non-therapeutic 
application of brain stimulation. The alleged effects of TES on attention, memory, 
learning, visuomotor performance and other neuropsychological functions have led to a 
growing industry in non-therapeutic enhancement tools, even though the long-term 
effects of TES are not well documented and the possible negative consequences of the 
technique are not completely ruled out. 
The regulatory landscape for TES devices is important and will likely evolve. We 
discussed the significance of potential outcome measures for therapeutic uses in the 
regulatory process, and explored strategies for obtaining the approval of therapies 
utilizing a combination of TES and pharmaceuticals. Differences in the regulatory 
pathways in different countries, and the benefits of harmonizing the regulatory policies 
were also mentioned. The question remained open whether the regulatory policies for 
medical devices should be extended to TES devices for neuroenhancement in order to 
promote the safe use of such devices.  
Questions pertaining to ethics and patient safety with regard to off-label and 
over-the-counter uses of tDCS are very complex. One reason is that there is no clear 
distinction between medical and non-medical approaches (e.g., neuroenhancement 
applications in healthy individuals cover potential therapeutic indications in patients). 
Other problems are related to the diverse and multifaceted regulations in different 
countries and to the quality of performed trials. For example, recent findings even 
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suggest that devices and methods (cranial electrotherapy) that are cleared for use in 
psychiatric disorders are supported by low-quality data only (Philip et al. , 2017). 
An emerging market for direct-to-consumer non-therapeutic products raises 
questions about safety and efficacy in the home setting, since the safety of unsupervised 
use is an area of concern. Accordingly, it is no surprise that the DIY tDCS direction is 
rapidly expanding. On the most popularly used Reddit tDCS forum, many comments can 
be seen that indicate a lack of understanding of tDCS uses and effects, and which suggest 
that the application of stimulation by some users may be unsafe. 
In summary, in this guideline we provide an overview of the technical parameters 
and basic principles of TES, either used alone or combined with other methodologies. 
We address safety aspects of the stimulation, including reporting of AEs in healthy 
subjects and different patient populations. Finally, we summarize recent regulatory 
issues and recommended checklists and questionnaires for reporting. These forms are 
available and can be downloaded freely from the internet: http://www.neurologie.uni-
goettingen.de/downloads.html.  
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Table 1. AEs of galvanism. For detailed explanation see text. 
 
Althaus (1860) 
p. 88 – Stabbing Pain on the skin which leads to an erythema 
p. 89 – strong convulsions similar to a poisoning with Strychnine 
p. 91 – clonic convulsions  
p. 93 – tetanic convulsions of the extremities during the stimulation of the spinal cord 
p. 96 – Lightning sensation during stimulation of the visual organ 
p. 101 – tickling and pain sensation in the olfactory organ 
p. 102 – sensation of hearing sounds during the stimulation of the hearing organ 
p. 104/106 – gustatory sensation and abundant secretion of saliva after stimulating the 
trunk of the chorda tympani 
p. 162 – sympathetic reaction after galvanizing the cervical part of the sympathetic chain 
p. 164 – increased heartbeat 
 
Augustin (1801) 
p. 46 – strong shock while touching the device with wet fingers 
p. 55/56 – impact of the voltaic pile on the organs of the human body 
p. 57 – impact of the voltaic pile on the sensory organs (burning pain, vibrating light) 
p. 58 – fainting during stimulation with wire between mouth and nose with a pile 
constructed out of 20-30 layers  
p. 58/59 – strong hearing sensation, vertigo 
p. 60 – heat sensation during contact with the tongue 
p. 64 – sickness after long stimulation with a battery with 100 layers, eye inflammation, 
vertigo, headache 
p. 69 – patient becomes hypersensitive – cannot continue procedure 
p. 70 – battery with 40/50 layers leads to strong pain and convulsions  
 
Grapengiesser (1801) 
p. 18 – convulsive ascending and descending of the pharynx 
p. 60 – hearing sensation in the auditory passage (meatus acusticus) 
p. 62 – burning pain in the auditory passage / stabbing pain in the nose 
p. 72/73 – effects on the visual organ listed in tabular form 
p. 82/83 – different kind of pains while contact with zinc- or silverpole 
p. 88 – depression and excitation of the Nervus Ischiadicus 
p. 90 – rigidity and less movement in the region of the shoulder 
p. 95 – numbness while stimulating with the silverpole 
p. 98 – induction of paroxysm 
p. 109 – pain from feet to abdomen while stimulating the feet  
p. 139 – induction of deafness and hearing sensation  
p. 140 – increasing hearing sensations  
p. 168 – toothache after repetitive stimulation of the jawbone 
p. 169 – lightning sensation while applying brass conductors onto the cornea 
p. 235 – light vertigo, light hearing sensation and lightning sensations 
 
Hellwag (1802) 
p. 105 – gustatory sensation on the tongue, lightning sensation 
p. 108 – increased excitability of organs while stimulating with the zinc pole 
p. 121/122 – patient got a concussion after stimulating the tongue with a battery 
p. 123/124 – electric shock after stimulating with two conductors and one battery 
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p. 124 – lightning sensation with closed eyes – pain with open eyes 
p. 152/153 – stimulation of a young men with a tender body with a battery with six 
layers.  The sponge of the conductor chained with the zinc pole rests on the association 
of the left lacrimal bone / the other one on the Foramen supraorbitale → strong 
convulsions in both arms and strong lightning sensations (Pain lasted two days) 
p. 154 – hearing sensation and vertigo after stimulating with 30 layers / stimulating 
with up to 70 to 80 layers and a double-battery 
p. 157 – rash on the skin similar to scabies 
p. 176 – strong vertigo and hearing sensation after stimulating with 6 layers 
p. 185 – strong pain in the hand after stimulating with 20 layers 
 
Ziemssen (1864) 
p. 39 – pain after stimulating branches of the N. auriculo-temporalis 
p. 45 – tetanic convulsions after stimulating a hernia  
p. 48 – partial anemia and spastic constriction during stimulation of vessels 
p. 49 – hyperaemia of the skin  
p. 77 – unpleasant sensation while stimulating the skin nerves 
p. 158 – Stimulation of the median nerve leading to pain 
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Table 2. Examples of persisting skin lesions induced by tDCS 
 
Subjects/Patients Stimulation 
electrode 
position 
(polarity) 
Return 
electrode 
position 
(polarity) 
Current 
settings 
Session 
duration 
(minutes) 
Number 
of 
sessions 
AEs Reference 
3 patients with 
chronic tinnitus 
F3 (C) F4 (A) 1.5 mA, 0.043 
mA/cm2 
30 4 Skin lesions under 
anodal electrode 
(Frank et al., 
2010) 
1 patient with 
tempomandibular 
disorder 
M1 (C3 or 
C4)(A) 
Contralateral 
supraorbital 
(C) 
2 mA, 
electrode 
size is not 
reported 
20 5 Skin burn after the 
fifth sessions 
(Oliveira et al., 
2015) 
5 patients with 
depression 
F3 (A) contralateral 
supraorbital 
(C) 
2 mA, 0.057 
mA/cm2 
20 5 Skin lesions under 
cathodal electrode 
(Palm et al., 
2008a) 
1 healthy subject posterior 
superior 
temporal 
sulcus (C) 
supraorbital 
(A) 
0.75 mA, C: 
0.083 
mA/cm2 
A: 0.0075 
mA/cm2 
20 1 Contact dermatitis 
under both 
electrodes 
(Riedel et al., 
2012) 
3 patients with 
neuropathic pain 
secondary to spinal 
cord injury 
C3 or C4 (A) contralateral 
supraorbital 
(C) 
2 mA, 0.057 
mA/cm2 
20 2 -10 Skin lesions under 
cathodal electrode 
(Rodriguez et al., 
2014)  
1 healthy subject F3 (A) contralateral 
supraorbital 
(C) 
2 mA, 0.057 
mA/cm2 
26 1 Skin burn under 
cathodal electrode 
(Wang et al. , 
2015a) 
tDCS: transcranial direct current stimulation, A: anode, C: cathode; AE: adverse effect 
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Table 3. Adverse events in combined tDCS / rTMS studies in healthy volunteers 
  
Abbreviations: PS, priming stimulation; TS, test stimulation; M1, hand area of primary motor cortex; V1, primary visual cortex; RMT, resting motor threshold; AMT, 
active motor threshold; PT, phosphene threshold; rTMS, repetitive transcranial magnetic stimulation; PAS, paired associative stimulation; atDCS, anodal transcranial 
direct current stimulation; ctDCS, cathodal transcranial direct current stimulation; P, pulses.   
  
Site of PS/TS Priming stimulation Test stimulation Delay between 
PS/TS 
Adverse effects Reference 
M1 / M1 atDCS, 1mA, 10min 
ctDCS, 1mA, 10min 
5Hz rTMS, 90%RMT, 100P 5min None (Antal et al. , 2008b) 
V1 / V1 atDCS, 1.5mA, 20min 
 
ctDCS, 1.5mA, 20min 
5Hz rTMS, 85%RMT, 300P 
1Hz rTMS, 85%RMT, 600P 
5Hz rTMS, 85%RMT, 300P 
1Hz rTMS, 85%RMT, 600P 
15-20min None (Bocci et al. , 2014) 
M1 / M1 atDCS, 1.5mA, 15min 
ctDCS, 1.5mA, 15min 
6 x 5Hz rTMS 120%RMT, 10P <1min None (Cosentino et al. , 2012) 
M1 / M1 atDCS, 1mA, 10min 
ctDCS, 1mA, 10min 
5Hz rTMS, 100%AMT, 100P 10min None (Lang et al. , 2004) 
V1 / V1 atDCS, 1mA, 10min 
ctDCS, 1mA, 10min 
5Hz rTMS, 90%PT, 100P 5min None (Lang et al. , 2007) 
M1 / M1 atDCS, 1mA, 7min 
ctDCS, 1mA, 7min 
PASLTP (7min) 
 
<1min Not reported (Nitsche et al. , 2007b) 
M1 / M1 atDCS, 1mA, 10min 
ctDCS, 1mA, 10min 
1Hz rTMS, 90%RMT, 15min 10min None (Siebner et al. , 2004) 
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Table 4. Adverse events in combined tDCS / rTMS clinical studies. 
 
For abbreviations, see Table 2 
 
  
Site of 
PS/TS 
Patients Priming 
stimulation 
Test stimulation Delay between 
PS/TS 
Adverse 
effects 
Reference 
M1 / M1 Migraine with aura atDCS, 1mA, 
10min 
ctDCS, 1mA, 10min 
5Hz rTMS, 90%RMT, 
100P 
5min None (Antal et al., 2008b) 
M1 / M1 Migraine with aura, migraine 
without aura 
atDCS, 1.5mA, 
15min 
ctDCS, 1.5mA, 
15min 
6 x 5Hz rTMS 
130%RMT, 10P 
<1min, or 20min None (Cosentino et al. , 2014) 
M1 / M1 Writer’s cramp atDCS, 1mA, 
10min 
ctDCS, 1mA, 10min 
1Hz rTMS, 85%RMT, 
15min 
10min None (Quartarone et al. , 
2005) 
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Table 5: Summary of the main findings of tDCS review publications in pediatric populations. 
 
NIBS: noninvasive brain stimulation, tDCS: transcranial direct current stimulation, TMS: transcranial magnetic stimulation, AE: adverse effect 
Title of study Main findings Reference 
Noninvasive Brain Stimulation: The Potential for Use in 
the Rehabilitation of Pediatric Acquired Brain Injury 
NIBS may serve as a tool for pediatric neurorehabilitation, but 
many gaps in our knowledge must be filled before NIBS can be 
adopted as a clinical intervention 
(Chung and Lo, 
2015) 
Safety of noninvasive brain stimulation in children and 
adolescents. 
TMS and TES are safe modalities in children and adolescents (Krishnan et al., 
2015)*** 
Transcranial Direct Current Stimulation in Child and 
Adolescent Psychiatry. 
tDCS may be well tolerated and safe for children and adolescents 
with psychiatric and neurodevelopmental disorders, at present it is 
not possible to draw definite conclusions. 
(Muszkat et al. , 
2016) 
Transcranial direct current stimulation in children and 
adolescents: a comprehensive review. 
Overall, tDCS seems to be safe in pediatric population (Palm et al. , 2016a) 
Noninvasive Brain Stimulation in Pediatric Attention-
Deficit Hyperactivity Disorder (ADHD): A Review. 
The safety profile of tDCS excellent and the main documented AEs 
are an itching sensation and skin redness under the electrode 
(Rubio et al. , 2016) 
*** 
The use of noninvasive brain stimulation in childhood 
psychiatric disorders: new diagnostic and therapeutic 
opportunities and challenges. 
Although the utilization of TMS and tDCS remains limited in 
children, there is enough evidence for their rational, safe use in this 
population. 
(Rubio-Morell et al. , 
2011) *** 
Transcranial Direct Current Stimulation in Epilepsy. Induce suppression of epileptiform activity (San-Juan et al. , 
2015) * 
Transcranial direct current stimulation: a remediation tool 
for the treatment of childhood congenital dyslexia? 
The studies provide preliminary evidence in support for a 
therapeutic potential of non-invasive stimulation techniques in 
children and adolescents. 
(Vicario and 
Nitsche, 2013) 
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Table 6. Major reported AEs and related stimulation protocols in pediatric populations 
Study population, 
Number of subjects 
Age range 
or mean 
age (years) 
Montage; Electrode 
size 
Intensity, 
Duration, # of 
sessions 
AEs Reference 
Autism (n=24) 
 
5-8 F3 (A), shoulder 
contralateral (C); 
35 cm2 
1 mA; 20 min;#2 transient erythematous rash (Amatachaya et al. , 2015) 
 
Autism (n=24) 5-8 F3 (A), shoulder 
contralateral (C); 
35 cm2 
1 mA;20 min; #5 None (Amatachaya et al. , 2014) 
Various language 
disorders (n=14) 
5-12 Broca area (A), right 
supraorbital area (C); 
35 cm2 
2mA; 30 min.; #10 Slight mood changes, 
irritability, tingling, itching, 
headache, burning sensation, 
sleepiness, trouble 
concentrating 
(Andrade et al., 2014) 
Cerebral palsy (n=46) 13 left primary motor 
cortex (A), right 
shoulder (C) 
35cm2 
1 mA; 20 min; # 5 erythematous rash in 1 patient (Aree-uea et al. , 2014) 
Lennox-Gastaut 
Syndrome (n=22) 
6-15 
 
left M1 (C), right 
shoulder area (A), 35 
cm2  
2 mA; 30 min;# 5 
 
Mild skin burn 
 
(Auvichayapat et al. , 
2016) 
Epilepsy (n=36) 6-15 epileptogenic focus 
(C); right shoulder (A), 
35 cm2 
1 mA; 20 min None (Auvichayapat et al. , 
2013) 
ADHD (n=9) 6-16 F3 (A); right 
supraorbital area (C); 
35 cm2 
2 mA; 30 min; 5x Mild headache, neck pain, 
tingling, itching, burning, local 
redness, sleepiness 
(Bandeira et al. , 2016) 
Dystonia (n=9) 10-21 C3 or C4 (A or C); 
contralateral forehead, 
(A or C); 28 cm2 
2 mA; 9 min; # 5 Tingling at beginning, one 
patient with mild headache 
(Bhanpuri et al. , 2015) 
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Infantile cerebral 
paralysis (n=21) 
6-18 F1 (A); C3 (C), 600 
mm2 
0,2 -0,8 mA, Max 
35 min., #15 
slight heating under the 
electrodes 
(Bogdanov et al. , 1993) 
 
ADHD (n=46); healthy 
control (n=21) 
13-17 F8 (A), P7 (C), 35 cm2 1 mA; 20 min None (Breitling et al., 2016) 
Cerebral palsy (n=1) 5 F5 (Broca´s area) (A); 
contralateral 
supraorbital (C); 25 
cm2 
1 mA; 20 min; # 
10 
None (Carvalho Lima et al. , 
2016) 
Neurotypical children 
(n=24) 
9-19 respective primary 
motor cortex (A or C); 
contralateral forehead 
(A or C); 25 cm2 
A: 1 mA C: 1 mA 
C: 2 mA; 20 min 
None (Ciechanski and Kirton, 
2016) 
Cerebral palsy (n=20) 5-10 M1 (A); supraorbital 
region (C); 25 cm2 
1 mA; 20 min; # 
10 
None (Collange Grecco et al. , 
2015) 
Autism, Drug-
Resistant Catatonia 
(n=1) 
14 left DLPFC (A), right 
DLPFC (C); 25 cm2  
1 mA; 20 min; #28 None (Costanzo et al. , 2015) 
Dyslexia (n=18) 10-18 left parietotemporal 
(A); contralateral 
region (C); 25 cm2 
1 mA; 20min; #18 None 
 
(Costanzo et al. , 2016a) 
 
Dyslexia (n=19) 10-18 left parietotemporal 
(A); contralateral 
region (C); 25 cm2 
1 mA; 20 min; Mild tingling, itching, burning, 
sleepiness 
(Costanzo et al. , 2016b) 
Epilepsy (n=1) 4 right motor cortex (A); 
25-cm2 
1.2 mA; 20 min seizure after anodal tDCS (Ekici, 2015) 
Fibromyalgia (n=48) <=18 C3 (A), contralateral 
supraorbital (C); 35 
cm2 
2 mA; 20 min None (Fagerlund et al., 2015) 
Hemiparesis (n=13) 7-18 M1 lesioned 
hemisphere (A); M1 
nonlesioned 
0.7 mA; 10 min itching, burning, sleepiness, 
difficulty concentrating 
(Gillick et al., 2015b) 
89 
 
hemisphere (C); 
35 cm2 
Delayed neuro-
psychomotor 
development (n=1) 
3 C3 (A); supraorbital 
(C), 25 cm2 
1 mA; 20 min; #10 None (Grecco et al. , 2014b) 
Cerebral palsy (n=24) 4-11 M1 (A); supraorbital 
(C), 25 cm2 
1 mA; 20 min; #10 Not reported (Grecco et al., 2014a) 
Cerebral palsy (n=56), 
Healthy control 
(n=28) 
5-10 M1 (between Cz - C3 
or C4) (A); 
contralateral 
supraorbital (C); 25 
cm2 
1 mA; 20 min Not reported (Grecco et al. , 2016) 
 
Cerebral palsy (n=12) 4-12 M1 (A); supraorbital 
(C); 25 cm2 
1 mA; 20 min Not reported (Lazzari et al. , 2015) 
Childhood-onset 
schizophrenia (n=13) 
10-17 left and right DLPFC 
(n=8) (bilateral A); left 
and right STG (n=5) 
(bilateral C); in both 
cases R was placed on 
the non-dominant 
forearm;25 cm2 
2 mA; 20 min; #10 tingling, itching (Mattai et al., 2011) 
Healthy subjects 
(n=19) 
11-16 M1 (A or C); 
contralateral 
frontopolar (A or C); 
35 cm2 
1mA, 0.5 mA;10 
min 
tingling, itching (Moliadze et al., 2015b) 
ADHD (n=14) 10-14 F3 and F4 (A); 
ipsilateral mastoids 
(C); 13 mm outer 
diameter; 8 mm inner 
diameter: 0.503 cm2 
area 
0.497 mA/cm2; 5 
min; #5 
None (Munz et al., 2015) 
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ADHD (n=24), Healthy 
Control (n=12) 
10-14 F3 and F4; M1 and M2 
(C); 0.503 cm2 
0.497 mA/cm2; 5 
min; #5 
None (Prehn-Kristensen et al. , 
2014b) 
ADHD (n=15) 12-16 left DLPFC (A); Cz (C); 
round anode with a 
surface area of 314 
mm2 and a rectangular 
cathode with a surface 
area of 1250 mm2 
1mA, 20min #5 tingling, itching (Soff et al., 2016) 
 
Autism (n=10) 6-21 DLPFC (A); right 
supraorbital (C); 25 
cm2 
0.08 mA/cm2; 30 
min; 
None (Schneider and Hopp, 
2011) 
Focal, refractory 
spikes and waves 
during slow sleep 
(n=5) 
6-11  T7, FT7 or TP8 (C); 25 
cm2, A: 100 cm2 
1 mA; 20 min; #2 None (Varga et al., 2011) 
Epilepsy (n=1) 11 area above the left 
orbit (A); between P4 
and T4 (C); 25 cm2 
2 mA; 20 min; #10  Not reported (Yook et al. , 2011) 
Dystonia (n=14) 
 
7-19 
 
C3 or C4 (C); forehead 
contralateral (A); 35 
cm2 
1 mA; 9 min; #2 
 
None 
 
(Young et al. , 2014) 
 
Dystonia (n=11) 7-18 C3 or C4 (C); forehead 
contralateral (A); 
35 cm2  
1 mA; 9 min; #2 None (Young et al. , 2013) 
tDCS: transcranial direct current stimulation, A: anode, C: cathode, AE: adverse effect 
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Table78. Summary of studies of TES (tDCS, tACS) in older adults. 
tDCS        
N  Mean age / age 
range (years) 
Active electrode 
position; size (cm) 
Reference electrode 
position; size (cm) 
Current 
(mA) 
Duration 
(min); # of 
sessions* 
AEs** References 
25 63.7 / 56-80 L or R DLPFC 
(F3/4) (A); 35 cm2 
Contralateral cheek (C); 
35 cm2 
1.5 10 N/R (Berryhill and Jones, 2012) 
28 68.4 / 50-85 L and R DLPFC 
(F3/4) (A or C); 35 
cm2 
- 2 15 None / Slight itching during the first 30 sec of 
stimulation 
(Boggio et al., 2010) 
32 67.9 L or R DLPFC or 
parietal (A); 35 cm2 
Contralateral supraorbital 
(C); 35 cm2 
1.5 6 None 
 
(Brambilla et al. , 2015) 
23 51-69 L M1 (A); 45 cm2 R supraorbital (C) 2 20; 5x N/R (Dumel et al. , 2016) 
20  66.5 / 61-83 L DLPFC (A); 35 
cm2 
R shoulder (C) 2 10 Itchiness (26/21%), burning (21/37%), heat (5/0%), 
pinching (74/68%), iron taste (11/11%), effect on 
performance (5/5%)1 2B 
(Fertonani et al., 2014) 
20 62.1 / 50-80 R temporo-parietal 
(A); 35 cm2 
L supraorbital (C); 100 
cm2 
1 20 N/R 
 
(Floel et al. , 2012) 
20 68.3 L M1 (A); 35 cm2 R supraorbital (C); 51 cm2 1 30 N/R (Fujiyama et al. , 2014) 
11 63.0 / 55-80 Ipsi M1 (A); 25 
cm², L M1-R M1 
(D) 
Contralateral supraorbital 
(C) 
1 15 None  
 
(Goodwill et al. , 2013) 
12 66.0 Ipsi M1 (A); 25 cm² Contralateral supraorbital 
(C) 
1 15 N/R (Goodwill et al. , 2015) 
22  
 
57.5 Ipsi Cerebellum 
(A); 25 cm² 
Ipsi buccinators muscle 
(C) 
2 15 None 
Rating2A of discomfort: sham 1.9 ± 0.1, anodal 1.5 ± 
0.1; Rating2A of pain: sham 1.3 ± 0.04, anodal 1.6 ± 0.2 
(Hardwick and Celnik, 2014) 
98 71.0 / 65-86 L or R DLPFC 
(F3/4) (A or C); 35 
cm² 
Vertex (A or C) 1 37.5 Greater levels of itchiness in real compared to sham 
stimulation 2B 
(Harty et al., 2014) 
16 73.4 / 65-83 L M1 (A); 25 cm² Contralateral supraorbital 
(C) 
1 20 N/R (Heise et al. , 2014) 
36 66.6 R M1 (A); 35 cm² Contralateral supraorbital 
(C); 100 cm² 
1 20 Itching, tingling when current was increased 
Rating2A of attention (>8), fatigue (<8), discomfort 
(<1.5): no differences and no changes from pre to post 
stimulation 
(Hoff et al., 2015) 
10 69.0 / 62-74 L IFG (A); 5x7  R supraorbital (C) 2 20 None / Mild tingling (Holland et al., 2011) 
10 69.0 / 56-87 L M1 (A); 25 cm² Contralateral supraorbital 
(C) 
1 20 None 
Rating2A of attention, fatigue, discomfort: no 
differences  
(Hummel et al., 2010) 
72  64.4 / 55-73 R PFC (F4) or Contralateral cheek (C) 1.5 10; 10x N/R (Jones et al. , 2015) 
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parietal (P4) (A); 35 
cm² 
 
20 66.6 / 60-77 L/R parietal (P3/4) 
(A); 25 cm² 
Contralateral supraorbital 
(C); 35 cm² 
1 15 Slightly more burning sensation during active 
stimulation sessions, tingling, itching2B 
(Learmonth et al., 2015) 
20 68.2 / 61-77 L M1 (C3); 5x7, L 
M1-R M1 (D) 
Right supraorbital (A); 
100 cm² 
1 30 None 
 
(Lindenberg et al., 2013) 
32  67.9 L/R DLPFC or 
parietal (A); 35 cm² 
Contralateral supraorbital 
(C) 
1.5 6 Itching, irritation2B (Manenti et al., 2013) 
37 61 L PFC (F3) (A); 35 
cm² 
Right supraorbital (C) 0.8-2³ 20 None2B 
 
(Manor et al., 2016) 
20 68.0 / 60-76 L IFG (A) Right supraorbital (C), 
100 cm² 
1 20 None (Meinzer et al. , 2013) 
18 68.4 / 61-77 L M1 (C3) (A); 35 
cm², L M1-R M1 
(D) 
Right supraorbital (C); 
100 cm²- 
1 30 None 
 
(Meinzer et al. , 2014b) 
30 69.0 / 65-75 L DLPFC (F3) (A); 
35 cm² 
Right supraorbital (C), 
100 cm² 
1 or 2 25 None 
 
(Nilsson et al., 2015) 
38 63.2 L M1 or R 
cerebellum (A); 35 
cm² 
Contralateral supraorbital 
(M1 tDCS) or L trapezius 
muscle (cerebellar tDCS) 
(C) 
2 17 N/R (Panouillères et al. , 2015) 
8 75.0 / 63-84 L M1 (A); 25 cm² Contralateral supraorbital 
(C) 
1 20 Mild tingling, burning (during the initial 30 sec of 
anodal/sham) 
(Parikh and Cole, 2014) 
40  69.7 L and R DLPFC 
(F3/4) (A); 25 cm² 
Non-dominant arm (C) 2 30; 10x None 
 
(Park et al. , 2014) 
54 66.9 / 60-82 L M1 (A); 25 cm² Contralateral supraorbital 
(C); 51 cm² 
1.5 20 N/R 
 
(Puri et al. , 2015) 
14   65.0 / 55-69 L or R anterior 
temporal (T3/4) 
(A); 35 cm² 
Contralateral cheek (C) 1.5 15 N/R (Ross et al. , 2011) 
36  67.2 L DLPFC (F3) (A); 
35 cm² 
R supraorbital (C) 1.5 15 Itching, irritation2B (Sandrini et al., 2014) 
28 68.9 L DLPFC (F3) (A); 
35 cm² 
R supraorbital (C) 1.5 15 Itching, irritation at the beginning of anodal/sham 
stimulation2B 
(Sandrini et al., 2016) 
20 63.0 L DLPFC (F3) (A); 
35 cm² 
R supraorbital (C) 2 20 None 
 
(Zhou et al. , 2015) 
15  68.5 / 55-88 L M1 (A or C); 25 
cm² 
R supraorbital (A or C) 1 20 N/R 
 
(Zimerman et al., 2013) 
        
tACS       
N Active electrode position; size (cm) Reference electrode 
position; size (cm) 
Current 
(mA), 
Duration 
(min); # of 
Adverse events / Stimulation-induced sensations**  
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* Number after semicolon indicates number of consecutive sessions. ** Were reported, numbers in brackets represent number/percentage of participants reporting the 
respective adverse event in active stimulation condition 
A, anodal; bi, bilateral stimulation with two anodal plus two reference electrodes; C, cathodal; D, dual; DLPFC, dorsolateral prefrontal cortex; IFG, inferior frontal cortex; Ipsi, 
ipsilateral to the dominant hand (mostly right-handed subjects); L, left; N/R, not reported; R, right. 
1 First number reflects adverse events during anodal-offline (before task) and second number reflects sensations reported for anodal-online (during task) performance. 2A/B 
Rating on 10-point/5-point scale (0/1=none/low, 5/10=strong/high). ³ Determined individually. 
  
frequen
cy 
sessions* 
12 L temporo-parietal (CP5); 35 cm² R supraorbital; 100 cm² 1; 6 Hz 20 Tingling (3), itching (1), tiredness (2), loss of 
concentration (2)2B 
(Antonenko et al., 2016) 
24 Parieto-occipital (Cz-Oz); 35 cm² - 1.5; 8-
12 Hz 
20; 5x N/R  
 
(Muller et al., 2015) 
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Table 8. tDCS treatment for emergent mania or hypomania 
 
Patients Stimulation 
electrode 
position 
(polarity) 
Return 
electrode 
position 
(polarity) 
Current settings Session 
duration 
(minutes) 
Number 
of 
sessions 
AEs Reference 
1 patient with 
unipolar 
depression 
F3 (A) contralateral 
supraorbital 
(C) 
1 mA, 0.029 
mA/cm2 
20 10 Hypomania (Arul-Anandam et 
al., 2010) 
1 patient 
withunipolar 
depression 
F3 (A) F4 (C) 2 mA, 0.06 
mA/cm2 
30 5 Hypomania (Baccaro et al., 
2010) 
1 patient with 
unipolar 
depression  
F3 (A) F4 (C) 2 mA, 0.06 
mA/cm2 
30 5 Mania (Brunoni et al. , 
2011c) 
1 patient with 
bipolar 
depression 
F3 (A) contralateral 
arm (C) 
2 mA 20 14 Hypomania (Galvez et al., 
2011) 
6 patients with 
unipolar 
depression 
F3 (A) F4 (C) 2 mA, 0.08 
mA/cm2 
30 12 4 hypomania and 2 
mania 
(Brunoni et al., 
2013a) 
 
1 patient with 
bipolar 
depression 
F3 (A) F4 (C) 2 mA, 0.08 
mA/cm2 
30 12 Hypomania (Pereira Junior 
Bde et al., 2015)  
tDCS: transcranial direct current stimulation, A: anode, C: cathode, AE: adverse events 
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TABLE 9. 
SCREENING QUESTIONNAIRE FOR 
TRANSCRANIAL ELECTRICAL STIMULATION (TES) 
 
 
  YES NO 
1 Do you have metal (except titanium) or electronic implants in the brain/skull 
(e.g., splinters, fragments, clips, cochlear implants, deep brain stimulation etc.)? If 
yes, please specify the type of metal and the location 
______________________________________________________________________________________________
______________________________________________ 
  
2 Do you have metal or any electronic device at other sites in your body, such as a 
cardiac pacemaker or traumatic metallic residual fragments? If yes, please specify 
the device and the location 
__________________________________________________________________ 
  
3 Did you ever have surgical procedures involving your head or spinal cord? If yes, 
please specify the locations 
____________________________________________________________________ 
  
4 Have you ever had a head trauma followed by impairment of consciousness?   
5 Do you have skin problems, such as dermatitis, psoriasis or eczema? If yes, please 
specify the location 
____________________________________________________________________  
  
6 Do you have epilepsy or have you ever had convulsions, a seizure?    
7 Did you ever have fainting spells or syncope?   
8 Are you pregnant or is there any chance that you might be?   
9 Are you taking any medications? If yes, please specify: 
__________________________________________________________________ 
 
  
10 Did you ever undergo transcranial electric or magnetic stimulation in the past? If 
yes, were there any adverse events? Please specify: 
____________________________________________________________________ 
  
 
An affirmative answer to one or more of questions do not represent an absolute contraindication 
to TES, but the risk-benefit ratio should be carefully balanced by the Principal Investigator of the 
research project or by the responsible (treating) physician. 
 
Name ____________________________ Surname _______________________________ 
 
Date  _________________________ Signature __________________________________ 
 
2017 
Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines 
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TABLE 10. A – SHORT VERSION 
 
POINTS OF RELEVANCE WITH KNOWN INFLUENCE ON OUTCOME OF TRANSCRANIAL 
ELECTRICAL STIMULATION (TES) 
 
A structured checklist increases the reproducibility of studies minimises deviations from a given protocol and diminishes 
variability. A structured checklist is thus the recommended procedure for enhancing reliability and comparability in 
publications of TES experiments/trials.  
 
Participant information 
 Age: 
 Gender: 
 Handedness: 
 Medication (Depending on the type of study an even more precise documentation may 
be necessary, measurement of drug levels may be considered), label and dose  
 Caffeine consumption:        cups per day (indicate the best currently relevant estimate) 
 Nicotine consumption          cigarettes per day (indicate the best currently relevant 
estimate) 
 Alcohol consumption:         drinks per day (indicate the best currently relevant estimate) 
(for comparability important that unit is given and comparable measures are noted) 
 
Procedures applied, Dose parameters (sufficient information about the stimulation parameters should 
be provided in order to replicate or model the stimulation dose independently based on these parameters)  
 Type of stimulation: 
 Metric to be used: (e.g., behavioral, cognitive, EEG, MEP, MRI): 
 Stimulation intensity (peak-to-baseline): 
 Stimulation duration:  
 Type and number of electrodes: 
 Electrode positions: 
 Electrode size: 
  target electrode: 
  return electrode : 
 
Other factors to be considered 
 Tasks during stimulation (if any): 
 Day time of the experiment (from - to):  
 Duration of the whole experiment including preparation: 
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Additional 
comments:__________________________________________________________________________________________________
_____________________________________________________________________________________________________________ 
 
TABLE 10. B – FULL VERSION 
 
POINTS OF RELEVANCE WITH KNOWN INFLUENCE ON OUTCOME OF TRANSCRANIAL 
ELECTRICAL STIMULATION (TES) 
 
A structured checklist increases the reproducibility of studies, minimises deviations from a given protocol and 
diminishes variability. A structured checklist is thus the recommended procedure for enhancing reliability 
and comparability in publications of TES experiments/trials.  
 
Participant information 
 Age: 
 Gender: 
 Racial group:  
Caucasian/White 
African  
Asian  
Hispanic  
Other race: 
Mixed (i.e. > 1 racial type): 
 Handedness: 
 Head size (distance in cm: inion - nasion, ear to ear distance) 
 Previous experience with TES (additional information of potential relevance):  
 Medication (Depending on the type of study an even more precise documentation may 
be necessary, measurement of drug levels may be considered), label and dose  
  Within last hours 
  Within last days 
  Within last months 
 Caffeine consumption (cups) (indicate the best currently relevant estimate): 
Within last 12 hours 
Average within last months 
 Nicotine consumption (cigarettes per day) (indicate the best currently relevant 
estimate): 
  Within last 4 hours (half life of Nicotine: 2 hours) 
  Within last 48 hours (half life metabolite cotinine: 10-37 hours) 
 Alcohol consumption (drinks) (indicate the best currently relevant estimate):: 
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  Within last 24 hours 
 Average with last months (how many months?)  
 Drugs (e.g. marijuana) consumption (to be specified): 
(for comparability important that unit is given and comparable measures are noted) 
 Hormonal/menstrual cycle of female subjects 
 First day of last menstruation 
 In case of patients non-neuropsychiatric comorbidities: 
 
Procedures applied, Dose parameters (sufficient information about the stimulation parameters 
should be provided in order to replicate or model the stimulation dose independently based on 
these parameters) 
 Type of stimulation (complicated waveforms with drawings): 
 Metric to be used: (e.g., behavioral, cognitive, EEG, MEP, MRI): 
 Product number and model of stimulator used (consider Nr. as encoded in case of 
multiple stimulators available): 
 Stimulation intensity (peak-to-baseline): 
 Stimulation duration:  
 Duration of ramping 
 Fragmented stimulation (interval duration) 
 Type and number of electrodes: 
 Electrode positions: 
 Electrode polarities in case of tDCS: 
 Position of cable fixation at electrode:  
 Electrode shape: 
 target electrode: 
 return electrode: 
 Electrode size: 
  target electrode: 
  return electrode : 
 Method of allocation of electrode position (neuronavigation, MEP hot spot, modeling 
etc): 
 Electrode-skin interface (any skin preparation steps): 
type of fixation: 
saline (molarity?) , in case of cream, brand: 
 
Other factors to be considered 
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 Tasks/status during stimulation (if any) : 
o Not specified or regulated 
o Specified/regulated: details ___________ 
 Day time of the experiment (from - to):  
 Attention (level of arousal) 
1. before stimulation: 
2. during stimulation (optimal results expected with relaxation, not during arousal 
or sleepiness): 
3. after stimulation: 
4. Number of hours in sleep during the last night: 
 
 Prior motor activity (i.e. cycling before stimulation, if yes, please define the duration): 
 Prior rest (sleep) before stimulation: 
 Duration of the whole experiment including preparation: 
 Number of years in education (of interest in special, e.g. in cognitive studies): 
 
Additional comments: 
_______________________________________________________________________________________________________________
_______________________________________________________________________________________________________________
_______________________ 
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TABLE 11. 
Questionnaire of sensations related to transcranial electrical 
stimulation (TES) 
 
(To be filled in by the participants and by the investigator) 
 
Investigator: 
Participant name/code:___________________________________________ Date:       /          /        | 
Experiment/Treatment: ________________________________  
No stimulations experienced before □ Experienced □ # of stimulations sessions before: 
……. 
Type of electrical stimulation used here_______ Intensity _____mA  (if known) 
Electrodes dimension: anode (if known) ___*___ cathode (if known) ___*___ (shape _______) 
other________________ 
 
Participant: 
Did you experience any discomfort during the electrical stimulation? Please indicate the degree 
of intensity of your discomfort according to the following scale: 
 
• None = I did not feel the sensation addressed 
• Mild = I mildly felt the sensation addressed 
• Moderate = I felt the sensation addressed 
• Strong = I felt the sensation addressed to a considerable 
degree 
 
In the first stimulation block I felt (to be filled in by subject, if it is possible please separate 
the sensations with regard to the electrode positions): 
 None Mild Moderate Strong 
Itching □ □ □ □ 
Pain □ □ □ □ 
Burning □ □ □ □ 
Warmth/Heat □ □ □ □ 
Metallic/Iron taste □ □ □ □ 
Fatigue/Decreased 
alertness 
□ □ □ □ 
Other □ □ □ □ 
4 hrs 
In case of perceived sensation, when did it begin? (this part can be multiplied and completed for 
each sensation, e.g. one for pain, one for itching etc and could/should be modified according to the 
type of experiments)  
□ At the beginning;            □ At approximately in the middle;            □ Towards the end of the 
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stimulation 
Duration (multiple options allowed) 
□ Only initially          □ It stopped in the middle of the block        □ It stopped at the end of the 
block 
How much did these sensations affect your general state? 
□ Not at all       □ Slightly      □ Considerably     □ Much      □ Very much 
Location of  sensations: 
□ Diffuse  □ localized  □ close to the electrode, (which one?)____________;  □ Other________ 
 
If you would like to provide more details, please briefly describe the experimented sensations in 
relation to the “Other” or “Fatigue” or ….. response: 
 
In the second stimulation block 
   (if there is more than one condition, repeat the list above here based on the block numbers)  
 
To be administered at the end of the entire experiment 
Do you believe that you received a real or placebo stimulation? 
 
In the first stimulation block/day/week:  □ real  □ placebo  □ I don’t 
know 
 
In the second stimulation block/day/week: □ real  □ placebo  □ I don’t know 
 
Investigator: 
Please report any adverse event/problem (typically skin irritation and redness – separately for 
the electrodes -, headache, scalp pain, dizziness, or others, please specify) that occurred and rate 
the event/problem on a scale from 0 to 3 as previously described. 
_______________________________________________________________________________________________________________
_______________________________________________________________________________________________________________
_______________________________________________________________________________________________________________
_____________________________________________________________________________ 
 
Additional comments: 
_______________________________________________________________________________________________________________
_______________________________________________________________________________________________________________
_____________________________________________________________________________________________________ 
 
 
A structured questionnaire on intensity and frequency of AEs increases safety, when 
transcranial electrical stimulation is used. It is a recommended procedure for publication of TES 
experiments/trials.  
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Figure legends 
Figure 1. Magnitude of the electric field in the cortex, in V/m. The maximum value of the 
electric field in the cortex was 0.34 V/m. The 7x5cm2 electrodes were placed over the 
left hand knob and above the contralateral eyebrow, and the current was set to 1 mA. 
The three slices pass through the center of the hand knob. 
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